Browse by Track

Type here to filter the list

Adult Clinical Trials - Immunologic
Friday, Nov 22
11:50 am

LTBK-08 - Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
Location: Grand Canyon Ballroom
Timothy F. Cloughesy – University of California Los Angeles
Friday, Nov 22
2:30 pm

LTBK-12 - EORTC 26951, randomized study of adjuvant PCV after 59.4 Gy radiotherapy: very long term follow-up.
Location: Grand Canyon 1-6
Martin van den Bent – Erasmus University Medical Center
Friday, Nov 22
8:02 pm

ATIM-16 - Validation of response to neoadjuvant anti-PD-1 immunotherapy in recurrent glioblastoma
Location: Wildflower B
Frances Chow – University of California, Los Angeles
Friday, Nov 22
7:30 pm

ATIM-02 - A new source of neoantigens for pediatric and adult brain cancer vaccines
Location: Ballroom Lawn
stephen albert johnston – ASU
Friday, Nov 22
7:30 pm

ATIM-04 - Phase I immunovirotherapy trial of IL-12 expressing HSV-1 (M032) in pet dogs with spontaneous high grade gliomas: a preliminary report
Location: Ballroom Lawn
D. Mitchell Self – University of Alabama at Birmingham
Friday, Nov 22
7:30 pm

ATIM-08 - Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma
Location: Ballroom Lawn
Yazmin Odia – MIAMI CANCER INSTITUTE, BHSF
Friday, Nov 22
7:30 pm

ATIM-10 - Clinical predictors of response for recurrent/refractory glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA, WHO grade III) patients treated with the anti-TGF ß 2 RNA therapeutic OT-101
Location: Ballroom Lawn
Sanjive Qazi – Oncotelic
Friday, Nov 22
7:30 pm

ATIM-12 - Avelumab in newly diagnosed glioblastoma multiforme-the SEJ study
Location: Ballroom Lawn
Ian Lorimer, PhD – Ottawa Hospital Research Institute
Friday, Nov 22
7:30 pm

ATIM-18 - Survival of subjects with recurrent glioblastoma receiving intra-tumoral administration of IL-12 managed with low-dose dexamethasone
Location: Ballroom Lawn
Rimas Lukas – Northwestern Medicine
Friday, Nov 22
7:30 pm

ATIM-20 - A retrospective study evaluating the safety and survival of the combination of PD-1 immune checkpoint blockade and bevacizumab in recurrent glioblastoma
Location: Ballroom Lawn
Joshua Friedman – Icahn School of Medicine at Mount Sinai
Friday, Nov 22
7:30 pm

ATIM-22 - Phase I Trial of Drug Resistant Immunotherapy: A First-in-Class Combination of MGMT-modifiedγδ T Cells and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma Multiforme
Location: Ballroom Lawn
Louis B. Nabors – University of Alabama at Birmingham
Friday, Nov 22
7:30 pm

ATIM-24 - Dose finding and dose expansion trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG)
Location: Ballroom Lawn
Annick Desjardins – Duke University Medical Center
Friday, Nov 22
7:30 pm

ATIM-26 - Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)
Location: Ballroom Lawn
Andrew B. Lassman, MS, MD – Columbia University Irving Medical Center
Friday, Nov 22
7:30 pm

ATIM-28 - Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with tumor associated antigens) as adjunctive therapy following surgery plus concurrent chemoradiation in newly diagnosed GBM patients
Location: Ballroom Lawn
Daniela A. Bota – UCI SOM
Friday, Nov 22
7:30 pm

ATIM-32 - Predictors of improved survival following oncolytic virus treatment in patients with recurrent glioblastoma: gene expression analysis from the phase Ib G207 clinical trial
Location: Ballroom Lawn
James M. Markert – University of Alabama at Birmingham
Friday, Nov 22
7:30 pm

ATIM-34 - Single-cell RNA sequencing reveals dynamic immune response changes in glioblastoma patient with durable complete response to CMV pp65-LAMP RNA-pulsed dendritic vaccines
Location: Ballroom Lawn
Oleg Yegorov – Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL 32610
Friday, Nov 22
7:30 pm

ATIM-36 - TEM-GBM-001 study: autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-α2 & administered to patients with glioblastoma & an unmethylated MGMT promoter
Location: Ballroom Lawn
Andrew Zambanini, MB BS MRCP FFPM – Genenta Science
Friday, Nov 22
7:30 pm

ATIM-44 - A phase I first-in-human trial of two adenoviral vectors expressing HSV1-TK and FLT3L for treating newly diagnosed resectable malignant glioma: therapeutic reprogramming of the brain immune system
Location: Ballroom Lawn
Pedro R. Lowenstein – University of Michigan
Friday, Nov 22
7:30 pm

ATIM-46 - A Multicenter, Phase I, Trial of Radiation, Temozolomide and RRx-001 followed by Maintenance Temozolomide With or Without RRx-001 in Newly Diagnosed Glioblastoma Patients
Location: Ballroom Lawn
Nicholas A. Butowski – University of California San Francisco
Saturday, Nov 23
1:40 pm

ATIM-06 - Treatment of recurrent/refractory (R/R) anaplastic astrocytoma (AA, WHO grade 3) patients with anti-TGFß2 RNA therapeutic OT-101 versus temozolomide is associated with improved overall survival
Location: Grand Canyon 7
Fatih Uckun, MD, PhD – Oncotelic
Saturday, Nov 23
5:00 pm

ATIM-01 - Nivolumab and bevacizumab for recurrent glioblastoma; a translational trial in progress
Location: Ballroom Lawn
Simone Eibye – Department of Radiation Biology and Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen
Saturday, Nov 23
5:00 pm

ATIM-03 - Anti-TGFß2 RNA therapeutic OT-101 induces durable objective responses in patients with recurrent/refractory (R/R) glioblastoma multiforme (GBM, WHO grade 4) or anaplastic astrocytoma (AA, WHO grade 3)
Location: Ballroom Lawn
Fatih Uckun, MD, PhD – Oncotelic
Saturday, Nov 23
5:00 pm

ATIM-05 - A phase I study targeting newly diagnosed glioblastoma with anti-CD3 × anti-EGFR bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide
Location: Ballroom Lawn
Jungeun Kim – University of Virginia
Saturday, Nov 23
5:00 pm

ATIM-07 - Efficacy and safety of nivolumab in patients with first recurrence of glioblastoma: a multicenter, open-label, non-comparative study (ONO-4538-19)
Location: Ballroom Lawn
Naoki Kagawa – Departments of Neurosurgery, Osaka University Graduate School of Medicine
Saturday, Nov 23
5:00 pm

ATIM-09 - Clinical trial in progress: A study of neoadjuvant and adjuvant VB-111 for treatment of recurrent GBM
Location: Ballroom Lawn
Timothy F. Cloughesy – University of California Los Angeles
Saturday, Nov 23
5:00 pm

ATIM-13 - Multimodal immunotherapy with IO-VAC^® for patients with GBM: A single institution experience
Location: Ballroom Lawn
Stefaan Van Gool – IOZK
Saturday, Nov 23
5:00 pm

ATIM-15 - Sustained complete radiographic response and prolonged systemic immune activation in a patient with MGMT unmethylated midline glioblastoma receiving CMV pp65-LAMP RNA-pulsed dendritic cell vaccines
Location: Ballroom Lawn
Duane Mitchell – Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL 32610
Saturday, Nov 23
5:00 pm

ATIM-17 - A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined with Nivolumab (Nivo), Ipilimumab (Ipi) and Bevacizumab (Bev) in Patients (pts) with Recurrent High Grade Gliomas
Location: Ballroom Lawn
Solmaz Sahebjam – Moffitt Cancer Center and Research Institute, University of South Florida
Saturday, Nov 23
5:00 pm

ATIM-21 - The current status of Ad-SGE-REIC gene therapy for malignant glioma
Location: Ballroom Lawn
Kazuhiko Kurozumi – Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Saturday, Nov 23
5:00 pm

ATIM-23 - Preliminary findings of a phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma.
Location: Ballroom Lawn
Hui K. Gan – Olivia Newton-John Cancer Research Institute, Austin Health
Saturday, Nov 23
5:00 pm

ATIM-25 - PD-1 inhibition can be combined with IL-12 in subjects with recurrent glioblastoma
Location: Ballroom Lawn
Ennio A. Chiocca – Department of Neurosurgery, Brigham and Women’s Hospital | Harvard Medical School
Saturday, Nov 23
5:00 pm

ATIM-27 - Tumor mutational burden predicts response to Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in malignant glioma patients: Assessment of transcriptional and immunological correlates.
Location: Ballroom Lawn
David M. Ashley – Duke University Medical Center
Saturday, Nov 23
5:00 pm

ATIM-29 - Identifying immunological barriers to immunotherapy in patients with glioblastoma multiforme
Location: Ballroom Lawn
Michael P. Gustafson – Mayo Clinic
Saturday, Nov 23
5:00 pm

ATIM-35 - The associations between total lymphocyte counts after concomitant chemoradiation with overall survival in patients with newly diagnosed glioblastoma.
Location: Ballroom Lawn
Stephen Ahn – Seoul St.Mary's Hospital, The Catholic University of Korea
Saturday, Nov 23
5:00 pm

ATIM-37 - Phase II, open-label, single arm, multicenter study of avelumab with hypofractionated radiation (HFRT) for adult patients with secondarily transformed IDH-mutant glioblastoma (GBM)
Location: Ballroom Lawn
Sylvia C. Kurz, MD, PhD – NYU Langone Health
Saturday, Nov 23
5:00 pm

ATIM-39 - Phase 2 open-labeled study of adjuvant temozolomide plus Tumor Treating Fields plus Pembrolizumab in patients with newly diagnosed glioblastoma (2-THE-TOP)
Location: Ballroom Lawn
David D. Tran – Lilian Wells Department of Neurological Surgery, the University of Florida
Saturday, Nov 23
5:00 pm

ATIM-43 - Plasma extracellular vesicle miRNA signatures in GBM patients receiving an experimental immunotherapy
Location: Ballroom Lawn
Luz M. Cumba-Garcia – Mayo Clinic Graduate School of Biomedical Sciences
Saturday, Nov 23
5:00 pm

ATIM-48 - Multidimensional Personalized Response Assessment to Microglia Modulators in Glioblastoma Bioreactors
Location: Ballroom Lawn
Gregor Hutter – University hospital Basel
Saturday, Nov 23
5:00 pm

ATIM-49 - AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BiTE^®) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (rGBM)
Location: Ballroom Lawn
Mark A. Rosenthal – Peter MacCallum Cancer Centre
Sunday, Nov 24
8:45 am

ATIM-14 - Results of phase II clinical trial of oncolytic herpes virus G47Δ in patients with glioblastoma
Location: Grand Canyon 1-6
Tomoki Todo – Department of Surgical Neuro-Oncology, Institute of Medical Science, The University of Tokyo
Sunday, Nov 24
8:55 am

ATIM-33 - Interim Results of a Phase II Multi-center Study of Oncolytic Adenovirus DNX-2401 with Pembrolizumab for Recurrent Glioblastoma; CAPTIVE Study (KEYNOTE-192)
Location: Grand Canyon 1-6
Clark C. Chen – Department of Neurosurgery, University of Minnesota
Sunday, Nov 24
9:05 am

ATIM-47 - Nivolumab vs bevacizumab in patients with recurrent glioblastoma: exploratory analysis of MGMT methylation status and baseline corticosteroid use
Location: Grand Canyon 1-6
Michael Weller – Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich
Sunday, Nov 24
9:25 am

ATIM-42 - Double-Blinded, Placebo Controlled Phase 2 Study of ERC1671 in Recurrent Glioblastoma: OS Correlations with Initial and Maximum CD4+T Lymphocyte Count in the Peripheral Blood.
Location: Grand Canyon 1-6
Daniela A. Bota – UCI SOM
Sunday, Nov 24
9:35 am

ATIM-38 - GLITIPNI: a phase 1b clinical trial combining surgical resection with direct intracerebral injection of immune checkpoint inhibitors in patients with recurrent glioblastoma
Location: Grand Canyon 1-6
Johnny Duerinck, MD, PhD – UZ Brussel
Sunday, Nov 24
9:45 am

ATIM-30 - Combating recurrent glioblastoma with MDNA55, an interleukin-4 receptor targeted immunotherapy, through MRI-guided convective delivery
Location: Grand Canyon 1-6
John H. Sampson – Duke University Hospital
Sunday, Nov 24
9:50 am

ATIM-31 - Safety of Tumor-Specific Peptide Vaccine Targeting Isocitrate Dehydrogenase 1 Mutation in Recurrent Resectable Low Grade Glioma Patients
Location: Grand Canyon 1-6
Katherine B. Peters – Duke University Medical Center
Sunday, Nov 24
10:00 am

ATIM-40 - Circulating Myeloid-Derived Suppressor Cells Predict Favorable Response to Immune Checkpoint Therapy in a Randomized Trial of Nivolumab and Bevacizumab in Recurrent GBM
Location: Grand Canyon 1-6
Manmeet S. Ahluwalia – Cleveland Clinic
Sunday, Nov 24
10:05 am

ATIM-45 - Long term follow-up of a phase I/II study testing the toxicities and efficacy of pembrolizumab in combination with MRI-guided laser interstitial thermal therapy (LITT) in recurrent malignant gliomas
Location: Grand Canyon 1-6
Jian L. Campian, MD, Ph.D – Washington University School of Medicine
Adult Clinical Trials - Non-immunologic
Friday, Nov 22
1:30 pm

ACTR-58 - Baseline requirements for novel agents being considered for brain cancer efficacy trials: Report of an ABTC Workshop
Location: Grand Canyon 1-6
Stuart A. Grossman – Johns Hopkins University School of Medicine
Friday, Nov 22
1:40 pm

ACTR-24 - A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): The VERTU study.
Location: Grand Canyon 1-6
Mustafa Khasraw, MD – Duke University
Friday, Nov 22
1:50 pm

ACTR-14 - A prospective randomized study of concurrent chemoradiotherapy with temozolomide versus radiotherapy alone in patients with IDH wild-type/TERT promoter mutation grade II/III gliomas
Location: Grand Canyon 1-6
Yi-dong Chen – Beijing Shijitan Hospital, Capital Medical University
Friday, Nov 22
2:00 pm

ACTR-04 - BIOMARK: A phase II study of bevacizumab beyond progression for newly diagnosed glioblastoma: Safety, efficacy and prospective biomarker analysis
Location: Grand Canyon 1-6
Koichi Ichimura, MD, PhD – Division of Brain Tumor Translational Research, National Cancer Center Research Institute
Friday, Nov 22
2:10 pm

ACTR-32 - NRG Oncology RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Vs. Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Location: Grand Canyon 1-6
Christina Tsien – Washington University School of Medicine
Friday, Nov 22
2:20 pm

ACTR-13 - Final results with chemoradiotherapy for anaplastic oligodendroglial tumors from NRG Oncology/RTOG 9402
Location: Grand Canyon 1-6
Andrew B. Lassman, MS, MD – Columbia University Irving Medical Center
Friday, Nov 22
2:40 pm

ACTR-07 - Long-term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation in adult supratentorial low-grade glioma
Location: Grand Canyon 1-6
William Breen – Mayo Clinic
Friday, Nov 22
2:45 pm

ACTR-46 - Tumor Treating Fields combined with radiotherapy and temozolomide for the treatment of newly diagnosed glioblastoma: Final results from a pilot study
Location: Grand Canyon 1-6
rachel grossman – Tel-Aviv Medical Center
Friday, Nov 22
2:50 pm

ACTR-66 - A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent IDH1 mutant, low-grade glioma: Updated results
Location: Grand Canyon 1-6
Ingo K. Mellinghoff – Memorial Sloan Kettering Cancer Center
Friday, Nov 22
3:15 pm

ACTR-50 - Preservation of neurocognitive function & patient-reported symptoms with hippocampal avoidance (HA) during whole-brain radiotherapy (WBRT) for brain metastases: Long-term results of NRG Oncology CC001
Location: Grand Canyon 1-6
Terri S. Armstrong – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Friday, Nov 22
3:25 pm

ACTR-30 - Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG)
Location: Grand Canyon 1-6
Patrick Y. Wen – Dana-Farber Cancer Institute
Friday, Nov 22
7:30 pm

ACTR-06 - Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report
Location: Ballroom Lawn
John Langlands – DelMar Pharmaceuticals Inc.
Friday, Nov 22
7:30 pm

ACTR-10 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Location: Ballroom Lawn
Shwetal Mehta – Ivy Brain Tumor Center, Barrow Neurological Institute
Friday, Nov 22
7:30 pm

ACTR-12 - Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting
Location: Ballroom Lawn
John Langlands – DelMar Pharmaceuticals Inc.
Friday, Nov 22
7:30 pm

ACTR-16 - MATRix regimen for newly diagnosed primary diffuse B-cell lymphoma of the central nervous system: preliminary results
Location: Ballroom Lawn
Richard M. Green – Southern California Permanente Medical Group
Friday, Nov 22
7:30 pm

ACTR-20 - Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Location: Ballroom Lawn
Roberta Rudà – Dept Neuro-Oncology, University and City of Helath and Science Hospital
Friday, Nov 22
7:30 pm

ACTR-22 - Initial treatment of GBM with a ketogenic diet along with radiation and chemotherapy: clinical outcomes.
Location: Ballroom Lawn
Kenneth Schwartz – Michigan State Univrsity
Friday, Nov 22
7:30 pm

ACTR-26 - Safety and efficacy of bevacizumab plus TTFields in patients with recurrent glioblastoma (GBM): data from a phase II clinical trial
Location: Ballroom Lawn
Jaleh Fallah – Taussig Cancer Institute
Friday, Nov 22
7:30 pm

ACTR-28 - A call for increased role of neurosurgeons in surgical trials for non-gliomatous primary CNS tumors: A systematic review of the ClinicalTrials.Gov database
Location: Ballroom Lawn
Alireza Mansouri – University Health Network
Friday, Nov 22
7:30 pm

ACTR-34 - Single agent ONC201 in previously-treated, progressive adult H3 K27M-mutant glioma
Location: Ballroom Lawn
Isabel Arrillaga-Romany – Massachusetts General Hospital
Friday, Nov 22
7:30 pm

ACTR-38 - A single center study: Long-term outcomes of combined chemoradiationtherapy with temozolomide for newly diagnosed glioblastoma in Korean patient
Location: Ballroom Lawn
Kyeong-O Go – Department of Neurosurgery, Seoul National University Bundang Hospital
Friday, Nov 22
7:30 pm

ACTR-40 - Phase 2 safety and efficacy of AR-67 (7-t-butyldimethylsiltyl-10-hydroxycamptothecin) in patients with recurrent Glioblastoma Multiforme (GBM) or Gliosarcoma
Location: Ballroom Lawn
Priya Kumthekar – Northwestern University
Friday, Nov 22
7:30 pm

ACTR-42 - PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma [NCT NCT02023905]
Location: Ballroom Lawn
Jennie W. Taylor – Division of Neuro-Oncology UCSF
Friday, Nov 22
7:30 pm

ACTR-44 - Feasibility, pharmacodynamics, and biologic activity of the GLioma Atkins-based Diet (GLAD) for preventing tumor recurrence in glioma patients
Location: Ballroom Lawn
Karisa C. Schreck, MD PhD – Johns Hopkins University School of Medicine
Friday, Nov 22
7:30 pm

ACTR-48 - Clinical development targeting AXL in recurrent glioblastoma
Location: Ballroom Lawn
Ichiro Nakano – University of Alabama at Birmingham
Friday, Nov 22
7:30 pm

ACTR-56 - Phase II trial of nilotinib in PDGFR-alpha enriched recurrent glioblastoma
Location: Ballroom Lawn
David Picconi, MD, PhD – UC San Diego Moores Cancer Center
Friday, Nov 22
7:30 pm

ACTR-60 - A phase 2, historically controlled study testing the efficacy of TTFields with adjuvant temozolomide in high-risk WHO grade II and III astrocytomas (FORWARD)
Location: Ballroom Lawn
Annie M. Allen – Lilian Wells Department of Neurological Surgery, the University of Florida
Friday, Nov 22
7:30 pm

ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O₆-methylguanine-methyltransferase (MGMT) promoter status
Location: Ballroom Lawn
Patrick Y. Wen – Dana-Farber Cancer Institute
Saturday, Nov 23
11:12 am

ACTR-11 - Second interim and 1^st molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.
Location: Grand Canyon Ballroom
Martin van den Bent – Erasmus University Medical Center
Saturday, Nov 23
11:50 am

ACTR-21 - A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in Epidermal Growth Factor Receptor (EGFR) amplified (amp) newly diagnosed glioblastoma (nGBM)
Location: Grand Canyon Ballroom
Andrew B. Lassman, MS, MD – Columbia University Irving Medical Center
Saturday, Nov 23
1:45 pm

ACTR-09 - A phase 0 pharmacodynamic and pharmacokinetic study of everolimus in vestibular schwannoma (VS) and meningioma patients
Location: Grand Canyon 1-6
Matthias Karajannis – Memorial Sloan Kettering Cancer Center
Saturday, Nov 23
1:30 pm

ACTR-57 - A phase 1/2 study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with a nine-emitter implantable ultrasound device in recurrent glioblastoma patients prior to carboplatin
Location: Grand Canyon 7
Alexandre Carpentier – Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires La Pitié-Salpêtrière, Service de Neurochirurgie, Paris, France
Saturday, Nov 23
5:00 pm

ACTR-18 - A phase Ib/II clinical trial of dodecafluoropentane emulsion (DDFPe) as a radiosensitizer in glioblastoma.
Location: Wildflower A
Evan Unger – NuvOx Pharma
Saturday, Nov 23
5:04 pm

ACTR-61 - A randomized Phase 2 trial of cediranib in combination with olaparib versus bevacizumab in patients with recurrent glioblastoma
Location: Wildflower A
Isabel Arrillaga-Romany, MD PhD – Massachusetts General Hospital
Saturday, Nov 23
5:08 pm

ACTR-53 - MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: lessons learned from the CeTeG/NOA-09 trial
Location: Wildflower A
Theophilos Tzaridis – Division of Clinical Neurooncology, Department of Neurology & Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn Medical Center
Saturday, Nov 23
5:12 pm

ACTR-63 - Phase I dose escalation study of procaspase activating compound-1 (PAC-1) in combination with temozolomide in patients with recurrent anaplastic astrocytoma or glioblastoma
Location: Wildflower A
Matthias Holdhoff – Johns Hopkins University School of Medicine
Saturday, Nov 23
5:16 pm

ACTR-62 - Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent high-grade astrocytoma in adults
Location: Wildflower A
Jing Wu – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Saturday, Nov 23
5:20 pm

ACTR-52 - Phase 1 study of FT-2102, an inhibitor of mutant IDH1, in patients with relapsed/refractory IDH1 mutant gliomas: preliminary safety and clinical activity
Location: Wildflower A
Macarena I. De la Fuente – Sylvester Comprehensive Cancer Center, University of Miami
Saturday, Nov 23
5:24 pm

ACTR-70 - A Multisite Clinical Trial of Spectroscopic MRI-guided Radiation Dose Escalation in Glioblastoma Patients
Location: Wildflower A
Eric A. Mellon – University of Miami
Saturday, Nov 23
5:32 pm

ACTR-25 - Rethinking the Dogma: How Important is Treatment of the CSF in Patients with Primary CNS Lymphoma (PCNSL)?
Location: Wildflower A
Dawit G. Aregawi – Penn State Milton S. Hershey Medical Center
Saturday, Nov 23
5:00 pm

ACTR-01 - Phase I/II Study of Temozolomide Plus NimustineChemotherapy for Recurrent Malignant Gliomas:Kyoto Neuro-oncology Group
Location: Ballroom Lawn
Tomokazu Aoki – National Hospital Organization Kyoto Medical Center
Saturday, Nov 23
5:00 pm

ACTR-03 - Final results of a phase II study of hypofractionated radiotherapy with concurrent and adjuvant temozolomide in patients over 70 years old with newly diagnosed glioblastoma
Location: Ballroom Lawn
Mehran Yusuf – University of Louisville Hospital
Saturday, Nov 23
5:00 pm

ACTR-05 - Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
Location: Ballroom Lawn
Yong Kil Hong – Deparment of Neurosurgery, The Catholic University of Korea
Saturday, Nov 23
5:00 pm

ACTR-15 - Phase 1 trial of a ketogenic diet in patients receiving standard-of-care treatment for recently diagnosed glioblastoma
Location: Ballroom Lawn
Jethro Hu, MD – Cedars-Sinai Medical Center
Saturday, Nov 23
5:00 pm

ACTR-17 - Diagnostic utility of serum microRNA classification in diffuse glioma
Location: Ballroom Lawn
Makoto Ohno, Board Certified Member of the Japan Neurosurgical Society, Board Certified Member of Japanese Board of Cancer Therapy, Board Certified Member of Neurospinal Society of Japan, Board Certified Member of the Japanese Society for Neurovascular Therapy – Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital
Saturday, Nov 23
5:00 pm

ACTR-19 - Report on the combination of Axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma
Location: Ballroom Lawn
Ellina Schulz – University of Würzburg
Saturday, Nov 23
5:00 pm

ACTR-23 - Maintenance treatment with ibrutinib following first line methotrexate-based immuno-chemotherapy in elderly patients with primary CNS lymphoma (PCNSL). A Phase 2 open-label study
Location: Ballroom Lawn
Tali Siegal – rabin medical center
Saturday, Nov 23
5:00 pm

ACTR-27 - Evolution of the Neurosurgeon’s role in clinical trials for GBM: A systematic overview of the ClinicalTrials.Gov database
Location: Ballroom Lawn
Alireza Mansouri – University Health Network
Saturday, Nov 23
5:00 pm

ACTR-29 - A series of patients (pts) with recurrent GBM (rGBM) treated with ABT-414, bevacizumab (Bev) and CCNU
Location: Ballroom Lawn
Madhawa K. De Silva – Royal North Shore Hospital, St Leonards, NSW, Australia
Saturday, Nov 23
5:00 pm

ACTR-31 - The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER: TTFields in Germany in routine clinical care)
Location: Ballroom Lawn
Oliver Bähr – Neurologische Klinik, Klinikum Aschaffenburg-Alzenau
Saturday, Nov 23
5:00 pm

ACTR-33 - Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study
Location: Ballroom Lawn
Andrew B. Lassman, MS, MD – Columbia University Irving Medical Center
Saturday, Nov 23
5:00 pm

ACTR-35 - A study of race and socioeconomic status impacting therapeutic clinical trial enrollment in adult gliomas patients
Location: Ballroom Lawn
Ramin Morshed, MD – UCSF
Saturday, Nov 23
5:00 pm

ACTR-37 - Association between MGMT promoter methylation score and survival in patients with glioblastoma
Location: Ballroom Lawn
Carlos G. Romo – Johns Hopkins University School of Medicine
Saturday, Nov 23
5:00 pm

ACTR-39 - Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory (R/R) glioblastoma (GBM); phase 1b/2 study update
Location: Ballroom Lawn
Anna F. Piotrowski – Memorial Sloan Kettering Cancer Center
Saturday, Nov 23
5:00 pm

ACTR-41 - An argument that more adjuvant temozolomide therapy is better for glioma patients
Location: Ballroom Lawn
Victor A. Levin – Kaiser Permanente Redwood City Hospital
Saturday, Nov 23
5:00 pm

ACTR-43 - Genomic analysis of responders of phase II trial of temozolomide and TRC-102 (base excision repair inhibitor) in bevacizumab-naïve glioblastoma at first recurrence
Location: Ballroom Lawn
Manmeet S. Ahluwalia – Cleveland Clinic
Saturday, Nov 23
5:00 pm

ACTR-47 - Phase-III Trial of Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma (NCT03632135)
Location: Ballroom Lawn
Tulika Ranjan – AHN Cancer Institute
Saturday, Nov 23
5:00 pm

ACTR-49 - Initial experience with scalp preservation and radiation plus concurrent alternating electric tumor-treating fields (SPARE) for glioblastoma patients
Location: Ballroom Lawn
Andrew J. Song – Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA
Saturday, Nov 23
5:00 pm

ACTR-51 - Remarkable Response of a Patient with Secondary GBM to a Histone Deacetylase Inhibitor
Location: Ballroom Lawn
Hui-Kuo Shu – Emory University
Saturday, Nov 23
5:00 pm

ACTR-55 - Optimized treat-resect-treat study design for convection-enhanced delivery of a first-in-class biologic in the treatment of glioblastoma
Location: Ballroom Lawn
Amanda Immidisetti – OncoSynergy, Inc.
Saturday, Nov 23
5:00 pm

ACTR-59 - A Phase 1 study of BPM31510 plus vitamin K in subjects with high-grade glioma that has recurred on a bevacizumab‑containing regimen
Location: Ballroom Lawn
Seema Nagpal, MD – Stanford School of Medicine
Saturday, Nov 23
5:00 pm

ACTR-67 - Patterns of care and impact on survival of first salvage therapy in high-risk grade II gliomas following initial temozolomide
Location: Ballroom Lawn
Alessia Pellerino – Dept Neuro-Oncology, University and City of Health and Science Hospital
Saturday, Nov 23
5:00 pm

ACTR-68 - Feasibility study of the EMulate Therapeutics™ Voyager system in patients with recurrent glioblastoma (GBM)
Location: Ballroom Lawn
Santosh Kesari – John Wayne Cancer Institute/Pacific Neuroscience Institute
Saturday, Nov 23
5:00 pm

ACTR-69 - Feasibility study of the EMulate Therapeutics™ Voyager system in patients with newly diagnosed glioblastoma
Location: Ballroom Lawn
Santosh Kesari – John Wayne Cancer Institute/Pacific Neuroscience Institute
Angiogenesis and Invasion
Friday, Nov 22
2:20 pm

ANGI-02 - Genome-wide shRNA screen identifies candidate genes driving glioblastoma invasion
Location: Grand Canyon 7
Simone P. Niclou – NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health
Friday, Nov 22
2:25 pm

ANGI-03 - Pharmacological targeting of apelin/APLNR signaling blunts therapy resistance to VEGFA/VEGFR2 anti-angiogenic treatment in glioblastoma.
Location: Grand Canyon 7
Roland E. Kälin – Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Germany
Friday, Nov 22
7:30 pm

ANGI-04 - A novel TROY-JAK1 signaling complex in glioblastoma invasion
Location: Ballroom Lawn
Zonghui Ding – Mayo Clinic Arizona
Friday, Nov 22
7:30 pm

ANGI-06 - Function of Formin-like 1 (FMNL1) in Glioblastoma Multiforme
Location: Ballroom Lawn
Nayuta Higa – Graduate School of Medical and Dental Sciences, Kagoshima University
Friday, Nov 22
7:30 pm

ANGI-08 - An annexin A2-regulated phenotypic shift in glioma
Location: Ballroom Lawn
Yuji Matsumoto – Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Saturday, Nov 23
5:00 pm

ANGI-05 - Origin of Microvascular Proliferation in Pilocytic Astrocytoma - MVP in pilocytic astrocytoma might partially comprise tumor-derived cells
Location: Wildflower B
Shinji Yamashita, MD – Department of Neurosurgery, University of Miyazaki
Saturday, Nov 23
5:04 pm

ANGI-10 - Chemotherapeutic stress induces transdifferentiation of glioblastoma cells to promote vascular mimicry
Location: Wildflower B
Shivani Baisiwala – Northwestern University
Saturday, Nov 23
5:00 pm

ANGI-01 - Identification of invasion-deterministic transcription factors in glioblastoma using integrative transcriptome analysis
Location: Ballroom Lawn
Seok-Gu Kang – Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine
Saturday, Nov 23
5:00 pm

ANGI-07 - Novel fusion gene PTPRZ1-MET promotes gliomas angiogenesis by up-regulating exocrine protein IGF2BP3
Location: Ballroom Lawn
Yanwei Liu – Department of Radiation Therapy, Beijing Tiantan Hospital, Capital Medical University
Saturday, Nov 23
5:00 pm

ANGI-11 - Sex differences in imaging-based assessment of glioblastoma invasion
Location: Ballroom Lawn
Susan Christine Massey – Mayo Clinic
Saturday, Nov 23
5:00 pm

ANGI-13 - Plexin-B2 facilitates diffuse glioma invasion by regulating cell adhesion and acto-myosin dynamics
Location: Ballroom Lawn
Yong Huang – Icahn School of Medicine at Mount Siani
Cell Biology and Metabolism
Friday, Nov 22
7:30 pm

CBMT-04 - Molecular mechanism of OLIG2-CDK2 interaction in glioma cells
Location: Ballroom Lawn
Norihiko Saito – Toho University Ohashi Medical Center
Friday, Nov 22
7:30 pm

CBMT-06 - High levels of GATA-4 in malignant meningioma lead to lower miR-497~195 cluster expression in tissue and blood
Location: Ballroom Lawn
Clemens Oliver Hanemann – Institute of Translational and Stratified Medicine, University of Plymouth
Friday, Nov 22
7:30 pm

CBMT-08 - In vivo evaluation of pentose phosphate pathway activity in orthotopic glioma using hyperpolarized δ-[1-¹³C]gluconolactone
Location: Ballroom Lawn
Georgios Batsios – Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America
Friday, Nov 22
7:30 pm

CBMT-10 - Mutant isocitrate dehydrogenase 1 inhibition induces a unique MRS-detectable metabolic signature in low-grade gliomas
Location: Ballroom Lawn
Abigail R. Molloy – Department of Radiology and Biomedical Imaging, University of California, San Francisco
Friday, Nov 22
7:30 pm

CBMT-12 - FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas
Location: Ballroom Lawn
Ruthild G. Weber – Department of Human Genetics, Hannover Medical School
Friday, Nov 22
7:30 pm

CBMT-14 - The dielectric properties of brain tumor tissue
Location: Ballroom Lawn
Martin Proescholdt – University Regensburg Medical Center
Friday, Nov 22
7:30 pm

CBMT-16 - EGFRvIII expression confers chemosensitivity by increasing DNA mismatch repair protein expression and replication stress
Location: Ballroom Lawn
Susan C. Short – Leeds Institute of Medical Research at St James’s, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, United Kingdom
Friday, Nov 22
7:30 pm

CBMT-18 - The role of biomarker candidate gelsolin and its microRNAs in glioblastoma
Location: Ballroom Lawn
Mitsutoshi Nakada – Department of Neurosurgery, Kanazawa University, Kanazawa, Japan
Friday, Nov 22
7:30 pm

CBMT-24 - Characterization of primary cilium in recurrent glioblastoma: implications for new therapeutic targets.
Location: Ballroom Lawn
Quintino Giorgio D'Alessandris – Department of Neurosurgery, Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore
Friday, Nov 22
7:30 pm

CBMT-30 - Targeting nicotinamide adenine dinucleotide biosynthesis in CNS tumors
Location: Ballroom Lawn
Patrick J. Paddison – Fred Hutchsinson Cancer Research Center
Friday, Nov 22
7:30 pm

CBMT-34 - Modulating Dietary Tryptophan or Gut Microbiota Levels does not Improve the Efficacy of Combined Treatment with Radiation, anti-PD-1 mAb, and an IDO1 Enzyme Inhibitor in a Model of Glioblastoma
Location: Ballroom Lawn
Erik Ladomersky, PhD – Northwestern University, Feinberg School of Medicine, Department of Neurological Surgery
Friday, Nov 22
7:30 pm

CBMT-36 - Initial experience with hyperpolarized [2-¹³C]pyruvate MR imaging in patients with IDH-mutant glioma
Location: Ballroom Lawn
Adam Autry – University of California, San Francisco
Friday, Nov 22
7:30 pm

CBMT-38 - Therapeutic inhibition of the spliceosome in glioblastoma: changes form minor to major
Location: Ballroom Lawn
Tobias Bonifert, PhD – Fred Hutchinson Cancer Research Center
Friday, Nov 22
7:30 pm

CBMT-44 - Comprehensive characterization of the intrinsic apoptotic machinery reveals the molecular blocks responsible for resistance to cell death in glioblastoma
Location: Ballroom Lawn
Elizabeth G. Fernandez – UCLA
Friday, Nov 22
7:30 pm

CBMT-46 - MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7
Location: Ballroom Lawn
Yingyi Wang – The First Affiliated Hospital of Nanjing Medical University
Friday, Nov 22
7:30 pm

CBMT-48 - Targeting metabolic reprogramming with nanocurcumin in glioblastoma multiforme
Location: Ballroom Lawn
Meser Ali – Henry Ford Hospital
Saturday, Nov 23
2:15 pm

CBMT-25 - The KLF4^K409Q mutation in meningioma impairs Hif-1α degradation and can be harnessed for targeted therapy
Location: Grand Canyon 1-6
Niklas von Spreckelsen – Department of Neurosurgery, Brigham and Women’s Hospital | Harvard Medical School
Saturday, Nov 23
1:30 pm

CBMT-19 - The alternative lengthening of telomere (ALT) mechanism provides collateral sensitivity to lethal telomeric fusion induced by trapping PARP inhibitors.
Location: Grand Canyon 8-13
Joydeep Mukherjee – UCSF
Saturday, Nov 23
1:40 pm

CBMT-27 - Aberrant amino acid metabolism expose novel functional vulnerabilities in glioblastoma
Location: Grand Canyon 8-13
Anthony R. Guastella, PhD – Beaumont Health
Saturday, Nov 23
1:50 pm

CBMT-28 - Fatty acid oxidation provides metabolic plasticity to maintain growth in the dynamic microenvironment of glioblastoma.
Location: Grand Canyon 8-13
Shiva Kant – Beaumont Health
Saturday, Nov 23
2:00 pm

CBMT-29 - Promoting fatty acid storage by diacylglycerol-acyltransferase 1 protects glioblastoma against oxidative stress and maintains lipid homeostasis for rapid tumor growth
Location: Grand Canyon 8-13
Deliang Guo – Department of Radiation Oncology at The Ohio State University Medical Center
Saturday, Nov 23
2:10 pm

CBMT-42 - A genome-wide CRISPR-Cas9 screen for genes regulating quiescent-like states in glioblastoma
Location: Grand Canyon 8-13
Anoop Patel, MD – Department of Neurological Surgery, University of Washington
Saturday, Nov 23
2:20 pm

CBMT-15 - MET Inhibition Drives PGC1a Dependent Metabolic Reprogramming and Elicits Unique Metabolic Vulnerabilities in Glioblastoma
Location: Grand Canyon 8-13
Markus Siegelin, MD – Columbia University Medical Center
Saturday, Nov 23
2:30 pm

CBMT-43 - Integrated lipidomic and molecular analysis reveals a subset of glioblastoma vulnerable to ferroptosis
Location: Grand Canyon 8-13
Danielle Morrow – UCLA
Saturday, Nov 23
2:35 pm

CBMT-09 - Therapeutic effect of induction of polyglutamylation in high-dose methotrexate therapy to primary central nervous system lymphoma
Location: Grand Canyon 8-13
Kenji Fujimoto – Division of Brain Tumor Translational Research, National Cancer Center Research Institute
Saturday, Nov 23
2:40 pm

CBMT-47 - Modulation of NAD pathways as a therapeutic strategy for targeting IDH mutant glioma
Location: Grand Canyon 8-13
Julie J. Miller – Massachusetts General Hospital
Saturday, Nov 23
2:45 pm

CBMT-32 - EGFR suppresses p53 function through DNA-PKcs binding to p53: novel crosstalk between EGFR and TP53 in Glioblastoma
Location: Grand Canyon 8-13
W. K. Alfred Yung – University of Texas MD Anderson Cancer Center
Saturday, Nov 23
2:50 pm

CBMT-45 - Sex-specific Metabolic Adaptions in Glioblastoma
Location: Grand Canyon 8-13
Jasmin Sponagel – Washington University in St. Louis
Saturday, Nov 23
3:55 pm

CBMT-41 - Imaging a hallmark of cancer: hyperpolarized ¹³C-magnetic resonance spectroscopy can non-invasively monitor TERT expression in low-grade gliomas in vivo
Location: Grand Canyon 8-13
Pavithra Viswanath – Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America
Saturday, Nov 23
4:05 pm

CBMT-02 - Up-regulation of γ-glutamyl-transferase can be used to image glioblastoma using hyperpolarized γ-glutamyl-[1-13C]glycine MRS
Location: Grand Canyon 8-13
Georgios Batsios, PhD – Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America
Saturday, Nov 23
5:16 pm

CBMT-17 - Defective QKI-dependent lipid metabolism induces genomic instability and sensitizes glioblastoma to immunotherapy
Location: Wildflower C
Jian Hu – Department of Cancer Biology, University of Texas MD Anderson Cancer Center
Saturday, Nov 23
5:24 pm

CBMT-22 - Reversing the Warburg effect by targeting Nicotinamide Phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of NAD+ salvage pathway increases, chemosensitivity to temozolomide in glioma cells
Location: Wildflower C
Pratibha Sharma, PhD – The Ohio State University
Saturday, Nov 23
5:28 pm

CBMT-23 - Non-canonical functions of TERT in glioblastoma
Location: Wildflower C
Shayesteh R. Ferdosi – Translational Genomics Research Institute
Saturday, Nov 23
5:40 pm

CBMT-20 - Single-cell transcriptomics resolves cellular heterogeneity and oncogenic networks during malignant transformation of peripheral nerve sheath tumors
Location: Wildflower C
Lai Man Natalie Wu – CCHMC
Saturday, Nov 23
5:48 pm

CBMT-26 - Serial characterization of hyperpolarized [1-¹³C]pyruvate metabolism in patients with glioma and the influence of bevacizumab
Location: Wildflower C
Adam Autry – University of California, San Francisco
Saturday, Nov 23
5:52 pm

CBMT-40 - The Relationship Between Glioma and the Gut-Brain Axis
Location: Wildflower C
Yoshua Esquenazi – Mischer Neuroscience Institute / Department of Neurosurgery, University of Texas Health Science Center.
Saturday, Nov 23
5:00 pm

CBMT-01 - Alanine fuels energy metabolism of glioblastoma cells
Location: Ballroom Lawn
Kumar Pichumani – Houston Methodist Hospital and Research Institute
Saturday, Nov 23
5:00 pm

CBMT-03 - Evaluation of PET tracers to differentiate IDH1 mutant GBM
Location: Ballroom Lawn
Akiva Mintz – Columbia University
Saturday, Nov 23
5:00 pm

CBMT-05 - Genetic and epigenetic mechanisms regulating SCD inhibitor sensitivity in Glioblastoma
Location: Ballroom Lawn
Biplab Dasgupta – Cincinnati Childrens Hospital
Saturday, Nov 23
5:00 pm

CBMT-07 - Biomarkers of Aggressiveness in IDH mutant Glioma
Location: Ballroom Lawn
Tomohiro Yamasaki – National Institutes of Health
Saturday, Nov 23
5:00 pm

CBMT-11 - High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma
Location: Ballroom Lawn
Audrey Rousseau, MD, PhD – Angers University Hospital
Saturday, Nov 23
5:00 pm

CBMT-13 - 3DEP system to test the electrical properties of different cell lines as predictive markers of optimal tumor treating fields (TTFields) frequency and sensitivity
Location: Ballroom Lawn
Moshe Giladi – Novocure
Saturday, Nov 23
5:00 pm

CBMT-21 - TERT promoter-mutant glioblastomas exhibit dependency on telomerase
Location: Ballroom Lawn
Elisa Aquilanti – Dana Farber Cancer Institute
Saturday, Nov 23
5:00 pm

CBMT-31 - HDAC inhibition diminishes the growth of endogenous IDH mutant gliomas
Location: Ballroom Lawn
Lubayna Elahi – UCLA
Saturday, Nov 23
5:00 pm

CBMT-35 - Metabolic rewiring by ONC201/TIC10 and 2-Deoxyglucose has synergistic anti-glioblastoma activity
Location: Ballroom Lawn
Georg Karpel-Massler – University of Ulm
Saturday, Nov 23
5:00 pm

CBMT-37 - OSMR controls cellular respiration and resistance to therapy
Location: Ballroom Lawn
Ahmad Sharanek – McGill University, Lady Davis institute for Medical Research
Saturday, Nov 23
5:00 pm

CBMT-39 - Targeting metabolic pathways in hypoxia for Glioblastoma
Location: Ballroom Lawn
Laura Caflisch – Mays Cancer Center at UT Health San Antonio
Saturday, Nov 23
5:00 pm

CBMT-49 - Oxaloacetate alters glucose metabolism in glioblastoma: ¹³C isotopomer study
Location: Ballroom Lawn
Kumar Pichumani – Houston Methodist Hospital and Research Institute
Cell Signaling and Signaling Pathways
Friday, Nov 22
7:30 pm

CSIG-02 - Targeting constitutive activation of the EGFR-STAT1 axis decreases proliferation of meningioma tumour cells
Location: Ballroom Lawn
Clemens Oliver Hanemann – Institute of Translational and Stratified Medicine, University of Plymouth
Friday, Nov 22
7:30 pm

CSIG-04 - Pan-RTK inhibition of sLRIG1 mediates AXL downregulation in Glioblastoma
Location: Ballroom Lawn
Simone P. Niclou – NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health
Friday, Nov 22
7:30 pm

CSIG-10 - Role of c-Met/β1 integrin complex in the establishment of brain metastases
Location: Ballroom Lawn
Harsh Wadhwa – Stanford School of Medicine
Friday, Nov 22
7:30 pm

CSIG-12 - PREX1 links aberrant PI 3-kinase pathway signaling to maintenance of the neural stem cell-like phenotype of glioblastoma cells
Location: Ballroom Lawn
Ian Lorimer, PhD – Ottawa Hospital Research Institute
Friday, Nov 22
7:30 pm

CSIG-16 - Reconciling tumor heterogeneity in glioblastoma using a pathway-based approach
Location: Ballroom Lawn
Alvaro G. Alvarado, PhD – UCLA
Friday, Nov 22
7:30 pm

CSIG-20 - Effect of tumor-treating fıelds (TTFields) on EGFR phosphorylation in GBM cell lines.
Location: Ballroom Lawn
Michael Reinert – Laboratory for Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland (EOC)
Friday, Nov 22
7:30 pm

CSIG-24 - GABP links AMPK signaling to TERT regulation in a TERT promoter mutation dependent manner
Location: Ballroom Lawn
Andrew M. McKinney – University of California, San Francisco
Friday, Nov 22
7:30 pm

CSIG-26 - Is intrinsic apoptosis the signaling pathway activated by tumor-treating fields for glioblastoma?
Location: Ballroom Lawn
Kristen Carlson – BIDMC/Harvard Medical School
Friday, Nov 22
7:30 pm

CSIG-30 - miR-146a inhibits tumorigenesis and induces temozolomide sensitivity via affecting cancer stem cell properties in GBM
Location: Ballroom Lawn
Tiantian Cui – OSUCCC
Saturday, Nov 23
5:12 pm

CSIG-28 - Role of Alternative Splicing in Conferring Spatial Heterogeneity Signatures in GBM
Location: Wildflower C
Sadashib Ghosh – University of Alabama at Birmingham
Saturday, Nov 23
5:20 pm

CSIG-31 - Alternative receptor tyrosine kinase signaling as a resistance mechanism to ERK inhibition in high-grade gliomas.
Location: Wildflower C
Ann-Catherine J. Stanton – Children's Hospital of Pittsburgh, University of Pittsburgh
Saturday, Nov 23
5:00 pm

CSIG-01 - Na-K-Cl cotransporter protein in the pathogenesis of low-grade gliomas
Location: Ballroom Lawn
Lanxin Luo – Department of Neurology, University of Pittsburgh
Saturday, Nov 23
5:00 pm

CSIG-03 - STAT 3-based patient stratification in precision neuro-oncology.
Location: Ballroom Lawn
Beng-Ti Ang – National Neuroscience Institute
Saturday, Nov 23
5:00 pm

CSIG-07 - Targeting cell polarity proteins from the Scribble complex disrupts glioblastoma stem cell viability and invasion in neural tissue
Location: Ballroom Lawn
Somanath Kundu, PhD – SUNY Upstate Medical University
Saturday, Nov 23
5:00 pm

CSIG-09 - Proteomic analysis of meningioma cell-derived extracellular vesicles: first of a kind
Location: Ballroom Lawn
Franz Ricklefs – Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
Saturday, Nov 23
5:00 pm

CSIG-11 - Central nervous system tumor patients have elevated levels of circulating extracellular vesicles
Location: Ballroom Lawn
Franz Ricklefs – Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
Saturday, Nov 23
5:00 pm

CSIG-13 - Protein kinase Ci drives both tumor invasion and proliferation and is a compelling target for the treatment of glioblastoma.
Location: Ballroom Lawn
Rajappa S. Kenchappa – Mayo Clinic
Saturday, Nov 23
5:00 pm

CSIG-15 - Inhibition of the bHLH transcriptional networks by a mutated E47 protein leads to a strong anti-glioma activity in vitro and in vivo
Location: Ballroom Lawn
Marilin S. Koch – Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School
Saturday, Nov 23
5:00 pm

CSIG-19 - Cytomegalovirus infection leads to NF-kB dependent upregulation of c-MET and MGMT in glioblastoma and resistance to temozolomide in vivo
Location: Ballroom Lawn
Mykola Zdioruk – Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School
Saturday, Nov 23
5:00 pm

CSIG-21 - De-orphanizing GPR133 - an adhesion GPCR required for glioblastoma progression
Location: Ballroom Lawn
Joshua D. Frenster – New York University School of Medicine
Saturday, Nov 23
5:00 pm

CSIG-23 - NOTCH activation induced by HSV-1 encoded miRNA-H16 sensitizes oHSV-treated tumors to NOTCH inhibitor
Location: Ballroom Lawn
Yoshihiro Otani, MD, PhD – 3) Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston
Saturday, Nov 23
5:00 pm

CSIG-27 - PRC2-independent function of EZH2/HP1BP3 complex in glioma stem cells
Location: Ballroom Lawn
Junxia Zhang – The First Affiliated Hospital of Nanjing Medical University
Saturday, Nov 23
5:00 pm

CSIG-29 - Structural and functional studies of PID1, a novel growth suppressor in brain tumors
Location: Ballroom Lawn
Anat Erdreich-Epstein – Children's Hospital Los Angeles and University of Southern California
Sunday, Nov 24
8:45 am

CSIG-06 - Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR overexpression, but not phosphorylation
Location: Grand Canyon 7
Michael Weller – Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich
Sunday, Nov 24
8:55 am

CSIG-08 - Extracellular domain mutations in EGFR result in a hypersensitive receptor
Location: Grand Canyon 7
Pim French – Erasmus MC Cancer Institute
Sunday, Nov 24
9:05 am

CSIG-17 - Signaling pathway-based clustering of mass cytometry data uncovers cells associated with clinical progression in glioblastoma
Location: Grand Canyon 7
Alvaro G. Alvarado, PhD – UCLA
Sunday, Nov 24
9:15 am

CSIG-22 - Regulation of glioma stem cell self-renewal and tumorigenesis by carbohydrate binding proteins
Location: Grand Canyon 7
Ahmad Sharanek, PhD – McGill University, Lady Davis institute for Medical Research
Sunday, Nov 24
9:25 am

CSIG-25 - MTAP loss compromises DNA damage response in GBM cells
Location: Grand Canyon 7
Yiping He, PhD – Duke University
Sunday, Nov 24
10:00 am

CSIG-05 - TRPM7 induces mechanistic target of Rap1b through downregulation of miR-28-5p in glioma proliferation and invasion
Location: Grand Canyon 7
MINGLI LIU – MOREHOUSE SCHOOL OF MEDICINE
CNS Metastasis
Friday, Nov 22
3:35 pm

CMET-32 - DNA methylation alterations in lung adenocarcinomas that develop brain metastases
Location: Grand Canyon 1-6
Jeffrey A. Zuccato, MD – MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network
Friday, Nov 22
3:45 pm

CMET-36 - Immunotherapy versus standard of care in melanoma brain metastases with known BRAF status
Location: Grand Canyon 1-6
Addison E. Barnett – Cleveland Clinic
Friday, Nov 22
3:55 pm

CMET-22 - Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study
Location: Grand Canyon 1-6
Rebecca Heist – Massachusetts General Hospital
Friday, Nov 22
4:15 pm

CMET-33 - Phase II study of palbociclib in brain metastases harboring CDK pathway alterations
Location: Grand Canyon 1-6
Priscilla K. Brastianos – Massachusetts General Hospital
Friday, Nov 22
7:42 pm

CMET-27 - Evaluation of dynamin 2 (DNM2) as a therapeutic target in leptomeningeal metastatic disease
Location: Wildflower A
Sophia B. Chernikova, MS, PhD – Department of Neurosurgery, Stanford University
Friday, Nov 22
7:30 pm

CMET-02 - ESTABLISHING THE SAFETY AND EFFICACY OF A NEW MULTI-AGENT INTRATHECALTREATMENT PROTOCOL FOR PATIENTS WITH NEOPLASTIC MENINGITIS
Location: Ballroom Lawn
Samer G. Zammar – Penn State Health
Friday, Nov 22
7:30 pm

CMET-04 - Radiomics Features can Differentiate the EGFR Mutation Status of Brain Metastases from Non-Small Cell Lung Cancer
Location: Ballroom Lawn
Yae Won Park – Ewha Womans University Hospital
Friday, Nov 22
7:30 pm

CMET-06 - An Analysis of Response Endpoints for Brain Metastasis Patients Treated with Stereotactic Radiosurgery and PD(L)-1 Inhibitors
Location: Ballroom Lawn
Rupesh Kotecha, MD – Miami Cancer Institute
Friday, Nov 22
7:30 pm

CMET-08 - Cerebrospinal Fluid Carcinoembryonic Antigen Predict Prognosis in Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Location: Ballroom Lawn
Junjie Zhen – Guangdong Sanjiu Brain Hospital
Friday, Nov 22
7:30 pm

CMET-10 - Intracranial solitary pituitary metastasis: the implications from five cases
Location: Ballroom Lawn
changguo shan – guangdong sanjiu brain hospital
Friday, Nov 22
7:30 pm

CMET-12 - Efficacy of upfront immune checkpoint inhibitors in lung cancer brain metastasis
Location: Ballroom Lawn
Addison E. Barnett – Cleveland Clinic
Friday, Nov 22
7:30 pm

CMET-14 - Brain Metastases: a New Pathophysiology, a New Treatment Paradigm, and, Perhaps, a New Prognosis
Location: Ballroom Lawn
Richard Dowd – Tufts Medical Center
Friday, Nov 22
7:30 pm

CMET-18 - Impact of KRAS Mutation Status on the Efficacy of Immunotherapy in Lung Cancer Brain Metastases
Location: Ballroom Lawn
Addison E. Barnett – Cleveland Clinic
Friday, Nov 22
7:30 pm

CMET-24 - Plateau wave events: A common, curable, and routinely misdiagnosed syndrome in patients with neoplastic meningitis (NM)
Location: Ballroom Lawn
Samer G. Zammar – Penn State Health
Friday, Nov 22
7:30 pm

CMET-26 - In-vitro & in-vivo culture of patient (pt) derived CSF-CTCs in leptomeningeal disease (LMDz) from melanoma to identify novel treatment strategies
Location: Ballroom Lawn
Peter Forsyth – H. Lee Moffitt Cancer Center & Research Institute
Friday, Nov 22
7:30 pm

CMET-28 - Decreased frequency of brain metastases due to the use of PDL1-inhibitors in RCC
Location: Ballroom Lawn
Mark Damante, Jr. – The Ohio State University College of Medicine
Friday, Nov 22
7:30 pm

CMET-34 - Improvement of leptomeningeal disease following infectious meningitis
Location: Ballroom Lawn
Nicholas R. Metrus – MD Anderson Cancer Center
Friday, Nov 22
7:30 pm

CMET-38 - Prevalence and survival outcomes of urothelial carcinoma brain metastases
Location: Ballroom Lawn
Bryan Iorgulescu – Dana-Farber Cancer Institute
Friday, Nov 22
7:30 pm

CMET-40 - Impact of Whole Brain Radiotherapy on Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Location: Ballroom Lawn
Zhaoming Zhou – Guangdong Sanjiu Brain Hospital
Friday, Nov 22
7:30 pm

CMET-42 - Use of stereotactic radiosurgery and outcomes following radiotherapy for brain metastases in patients with primary lung cancer – an Australian population-based study
Location: Ballroom Lawn
Wee Loon Ong – Austin Health
Saturday, Nov 23
2:35 pm

CMET-20 - Analysis of nano-sized particle in human cerebrospinal fluid: a measurement of extracellular vesicle concentration change with miR-21 expression after chemotherapy for leptomeningeal carcinomatosis
Location: Grand Canyon 7
Ho-Shin Gwak – National Cancer Center Graduate School of Cancer Science and Policy
Saturday, Nov 23
2:40 pm

CMET-21 - A Phase IB Study of Proton Craniospinal Irradiation for the Treatment of Solid Tumor Leptomeningeal Metastases
Location: Grand Canyon 7
T. Jonathan Yang, MD, PhD – Memorial Sloan Kettering Cancer Center
Saturday, Nov 23
2:45 pm

CMET-29 - Detecting Tumor Mutations in Cerebrospinal fluid: Liquid Biopsy for the Diagnosis of Central Nervous System Metastases
Location: Grand Canyon 7
Mauli Shah – University of Texas Health Science Center, Department of Pathology and laboratory medicine, Houston Texas
Saturday, Nov 23
2:50 pm

CMET-30 - Comprehensive methylome analysis of EGFR-mutant primary lung adenocarcinoma and matched brain metastasis
Location: Grand Canyon 7
Yasin Mamatjan, PhD – MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Saturday, Nov 23
5:00 pm

CMET-01 - Immune checkpoint inhibitors for non-small cell lung cancer with brain metastasis: the role of gamma knife radiosurgery
Location: Ballroom Lawn
Min Ho Lee – Uijeongbu St. Mary’s Hospital, The Catholic University of Korea
Saturday, Nov 23
5:00 pm

CMET-03 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Location: Ballroom Lawn
Junjie Zhen – Guangdong Sanjiu Brain Hospital
Saturday, Nov 23
5:00 pm

CMET-05 - Evaluating radiation necrosis in patients with intracranial metastases from melanoma
Location: Ballroom Lawn
Victoria S. Edmonds – Mayo Clinic Arizona
Saturday, Nov 23
5:00 pm

CMET-07 - Tumor related impairments of neurocognitive functions in patients with brain metastases
Location: Ballroom Lawn
Junjie Zhen – Guangdong Sanjiu Brain Hospital
Saturday, Nov 23
5:00 pm

CMET-09 - A Unique Case of Primary Gliosarcoma with Metastasis to Sacrum on Bevacizumab
Location: Ballroom Lawn
Maya Hrachova, DO – UC Irvine Medical Center
Saturday, Nov 23
5:00 pm

CMET-11 - Response to stereotactic radiosurgery for multiple brain metastases based on histology-specific subtype status
Location: Ballroom Lawn
Sean Sachdev, MD – Department of Radiation Oncology, Malnati Brain Tumor Institute, Feinberg School of Medicine,Northwestern University
Saturday, Nov 23
5:00 pm

CMET-13 - The composition of newly-diagnosed brain metastases varies widely by patient demographics
Location: Ballroom Lawn
Bryan Iorgulescu – Dana-Farber Cancer Institute
Saturday, Nov 23
5:00 pm

CMET-15 - Sarcopenia independently and strongly predicts survival in patients undergoing spine surgery for metastatic tumors
Location: Ballroom Lawn
Hesham M. Zakaria – Henry Ford Hospital
Saturday, Nov 23
5:00 pm

CMET-17 - Renal cell carcinoma brain metastases treated with stereotactic radiation therapy and nivolumab does not alter lesional or clinical outcomes
Location: Ballroom Lawn
Homan Mohammadi – H. Lee Moffitt Cancer Center and Research Institute
Saturday, Nov 23
5:00 pm

CMET-19 - Questioning the Paradigm: Do CSF Cytology and MRI Scanning Identify the Same Disease in Patients with Neoplastic Meningitis (NM) – Data from an International NM Registry and a Meta-Analysis
Location: Ballroom Lawn
Christopher R. Messner – Penn State Milton S. Hershey Medical Center
Saturday, Nov 23
5:00 pm

CMET-23 - Impact of Systemic Therapy in Melanoma Brain Metastasis
Location: Ballroom Lawn
Addison E. Barnett – Cleveland Clinic
Saturday, Nov 23
5:00 pm

CMET-25 - Comparative efficacy of treatment paradigms for brain metastases – a systematic review
Location: Ballroom Lawn
Karanbir Brar – University of Toronto
Saturday, Nov 23
5:00 pm

CMET-31 - Whole brain radiotherapy versus stereotactic radiosurgery in poor-prognosis patients with 1 – 10 brain metastases: a randomized feasibility study
Location: Ballroom Lawn
Alan Nichol – BC Cancer
Saturday, Nov 23
5:00 pm

CMET-35 - Competing risks analysis of factors influencing development of leptomeningeal metastasis in breast cancer patients receiving stereotactic radiosurgery for limited brain metastases
Location: Ballroom Lawn
Michael Y. Zhang, MD, PhD – Department of Radiation Oncology, University of California, San Francisco
Saturday, Nov 23
5:00 pm

CMET-37 - Clinical Utility of Encyclopedic Tumor Analysis to Treat Patients with Brain Metastasis in Refractory Cancers.
Location: Ballroom Lawn
Timothy Crook – St. Luke’s Cancer Center, Royal Surrey County Hospital
Saturday, Nov 23
5:00 pm

CMET-39 - Disparities in stereotactic radiosurgery use and outcomes for melanoma brain metastases – an Australian population-based study
Location: Ballroom Lawn
Wee Loon Ong – Austin Health
Saturday, Nov 23
5:00 pm

CMET-41 - Outcomes following stereotactic radiosurgery (SRS) for limited brain metastases - an Australian single institutional experience
Location: Ballroom Lawn
Lilly Shen – Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre
Computational Omics
Friday, Nov 22
7:30 pm

COMP-02 - Mining-Guided Machine Learning Analyses Supports Grasping the Latest Trends on Neuro-Oncology
Location: Ballroom Lawn
Taijun Hana – Department of Neurosurgery, University of Tokyo
Friday, Nov 22
7:30 pm

COMP-06 - Probing glioblastoma and its microenvironment using single-nucleus and single-cell sequencing
Location: Ballroom Lawn
Sen Peng – TGen
Friday, Nov 22
7:30 pm

COMP-08 - Comprehensive RNA analysis of cerebrospinal fluid from leptomeningeal metastases
Location: Ballroom Lawn
Dina Polyak – Stanford University
Friday, Nov 22
7:30 pm

COMP-10 - The mutational profile of glioblastoma-derived cell-free DNA in plasma represents a distinct subset of the somatic mutations present in glioblastoma solid tumor DNA
Location: Ballroom Lawn
Hunter Underhill – University of Utah
Friday, Nov 22
7:30 pm

COMP-14 - Molecular profiling and cellular deconvolution of glioblastoma brain tumors using chromatin run-on and sequencing
Location: Ballroom Lawn
Mariano S. Viapiano – SUNY Upstate Medical University
Saturday, Nov 23
5:00 pm

COMP-17 - Large-scale transcriptomic characterization of primary and recurrent glioblastoma identifies gene expression signature of tumor response to standard therapy
Location: Wildflower C
Andrew Dhawan – Cleveland Clinic
Saturday, Nov 23
5:00 pm

COMP-03 - Quantitative image feature analysis in diffuse glioma – A valuable MR imaging biomarker for preoperative IDH mutation classification
Location: Ballroom Lawn
James Snyder, DO – Henry Ford Health System
Saturday, Nov 23
5:00 pm

COMP-05 - A drug association map of glioblastoma informs precision targeting of p53-dependent metabolic states
Location: Ballroom Lawn
Sven Nelander – Uppsala University
Saturday, Nov 23
5:00 pm

COMP-07 - Machine learning predicts progression and survival in glioma using radiohistogenomic features
Location: Ballroom Lawn
Jeffrey I. Traylor – The University of Texas MD Anderson Cancer Center
Saturday, Nov 23
5:00 pm

COMP-13 - Early tumor volume evolution adaptively predicts patient-specific response and progression risk to radiotherapy, pembrolizumab, and bevacizumab in recurrent high-grade glioma in a phase I trial
Location: Ballroom Lawn
Daniel Glazar – Moffitt Cancer Center
Saturday, Nov 23
5:00 pm

COMP-15 - Molecular and Clonal Evolution in Recurrent Metastatic Gliosarcoma
Location: Ballroom Lawn
Kevin J. Anderson – The Jackson Laboratory for Genomic Medicine
Sunday, Nov 24
10:30 am

COMP-16 - Comprehensive transcriptomic analysis of single cells from recurrent and primary glioblastoma to predict cell-type specific therapeutics
Location: Grand Canyon 8-13
Robert K. Suter – University of Miami
Sunday, Nov 24
10:40 am

COMP-11 - Single cell mass cytometry signaling profiles and a novel computational tool identify high risk glioblastoma cells
Location: Grand Canyon 8-13
Rebecca A. Ihrie, PhD – Vanderbilt University
Sunday, Nov 24
11:50 am

COMP-09 - A cancer drug atlas enables prediction of parallel drug vulnerabilities of glioblastoma
Location: Grand Canyon 8-13
Bart Westerman, PhD – Amsterdam UMC, Cancer Center Amsterdam
Sunday, Nov 24
11:55 am

COMP-12 - Single-cell transcriptome profiling of GBM tissue acute slice cultures for personalized drug screening
Location: Grand Canyon 8-13
Wenting Zhao – Department of Systems Biology, Columbia University Irvin Medical Center
Sunday, Nov 24
12:05 pm

COMP-04 - Modeling precision oncology for glioblastoma through integration of descriptive, functional, and network-based genomics
Location: Grand Canyon 8-13
Pia Hoellerbauer – Fred Hutchinson Cancer Research Center
Drug Discovery
Friday, Nov 22
3:35 pm

DDIS-28 - A high throughput screening platform to identify radiosensitizers for DIPG.
Location: Grand Canyon 8-13
Matt Clutter, PhD – Northwestern University
Friday, Nov 22
3:45 pm

DDIS-32 - MEK inhibitors induces neuronal differentiation in EGFR amplified glioma stem like cells
Location: Grand Canyon 8-13
Veerakumar Balasubramaniyan – UT MD Anderson Cancer Center, Houston, Texas
Friday, Nov 22
3:55 pm

DDIS-33 - Selective and Complete Inhibition of mTORC1 by Bi-steric mTOR Inhibitors Drives Therapeutic Response in Glioblastoma
Location: Grand Canyon 8-13
William A. Weiss – UCSF
Friday, Nov 22
4:25 pm

DDIS-03 - Development of a novel class of cGAS agonists to trigger STING pathway-dependent innate immune responses against Glioblastoma
Location: Grand Canyon 8-13
Alexander H. Stegh, PhD – Northwestern University
Friday, Nov 22
4:30 pm

DDIS-23 - CMV-Based Plasmid DNA Vaccine for GBM Using the UNITE Platform
Location: Grand Canyon 8-13
Amit Adhikari – Immunomic Therapeutics
Friday, Nov 22
7:30 pm

DDIS-29 - Brain-penetrant microtubule-targeting agent, ST-401, kills glioblastoma through a novel mechanism.
Location: Wildflower B
Nephi Stella – University of Washington
Friday, Nov 22
7:30 pm

DDIS-02 - Development of novel spray-type fluorescent probes for glioblastoma detection
Location: Ballroom Lawn
Yosuke Kitagawa – Department of Neurosurgery, Faculty of Medicine, The University of Tokyo
Friday, Nov 22
7:30 pm

DDIS-04 - Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02
Location: Ballroom Lawn
Emilie Le Rhun – Department of Neurology, University Hospital and University of Zurich
Friday, Nov 22
7:30 pm

DDIS-06 - Anticancer effects of the small molecule inhibitor SB747651A in glioblastomas
Location: Ballroom Lawn
Arnon M. Knudsen – University of Southern Denmark
Friday, Nov 22
7:30 pm

DDIS-18 - Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
Location: Ballroom Lawn
Muhammad Babar Khan – The Feinstein Institute for Medical Research
Friday, Nov 22
7:30 pm

DDIS-20 - Imipridone structure activity relationship uncovers ONC206 as the next bitopic DRD2 antagonist for oncology with differentiated receptor pharmacology
Location: Ballroom Lawn
Varun V. Prabhu, PhD – Oncoceutics, Inc.
Friday, Nov 22
7:30 pm

DDIS-22 - Drug screen in patient-derived IDHmut glioma stem cells identifies several FDA-approved antineoplastic agents
Location: Ballroom Lawn
Philip Dao Trong – University Hospital Heidelberg, Department of Neurosurgery
Friday, Nov 22
7:30 pm

DDIS-24 - Decrease in Glioblastoma Growth In Vitro with Treatment of Novel Analogs of Glucose Transporter Inhibitors
Location: Ballroom Lawn
Anita Hjelmeland – Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham
Friday, Nov 22
7:30 pm

DDIS-26 - High-throughput drug screening of meningiomas identifies HDAC inhibitors as promising targets across grades.
Location: Ballroom Lawn
Philip D. Tatman – University of Colorado
Friday, Nov 22
7:30 pm

DDIS-30 - Evaluation of the susceptibility of neurons derived from human induced pluripotent stem cells to anticancer drugs for CNS tumors
Location: Ballroom Lawn
Yonehiro Kanemura – Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital
Friday, Nov 22
7:30 pm

DDIS-34 - High-Throughput Drug Screening of FDA-approved Antineoplastic Drugs for the Treatment of Aggressive Meningiomas
Location: Ballroom Lawn
Gerhard Jungwirth – Department of Neurosurgery, University of Heidelberg
Friday, Nov 22
7:30 pm

DDIS-36 - BTP-7, a novel peptide for therapeutic targeting of malignant brain tumors
Location: Ballroom Lawn
Niklas von Spreckelsen – Department of Neurosurgery, Brigham and Women’s Hospital | Harvard Medical School
Saturday, Nov 23
5:00 pm

DDIS-01 - New drug discovery with drug re-positioning system toward GBM treatment
Location: Ballroom Lawn
Hiroyuki Michiue – Neutron Therapy Research Center, Okayama University
Saturday, Nov 23
5:00 pm

DDIS-05 - Identification of 2-fluoro palmitic acid as a potential therapeutic agent against glioblastoma
Location: Ballroom Lawn
SHABIERJIANG JIAPAER – Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
Saturday, Nov 23
5:00 pm

DDIS-07 - Identification of druggable molecular targets in meningioma
Location: Ballroom Lawn
Anh N. Tran, PhD – Northwestern University
Saturday, Nov 23
5:00 pm

DDIS-17 - Development of Brain-Penetrant EGFR Inhibitors for CNS Malignancies
Location: Ballroom Lawn
Jonathan Tsang – University of California, Los Angeles
Saturday, Nov 23
5:00 pm

DDIS-19 - Using matched primary and recurrent pediatric brain tumor orthotopic mouse models(PDOX) to illustrate the genetic revolution and to inform new anti-recurrent personalized therapies
Location: Ballroom Lawn
Yuchen Du – Texas Children's Cancer Center
Saturday, Nov 23
5:00 pm

DDIS-21 - In vitro microdialysis recovery of trametinib
Location: Ballroom Lawn
Carlos G. Romo – Johns Hopkins University School of Medicine
Saturday, Nov 23
5:00 pm

DDIS-25 - Pentamidine; a new chemotherapy targeting on glioma stem like cells
Location: Ballroom Lawn
Sho Tamai – Kanazawa University
Saturday, Nov 23
5:00 pm

DDIS-27 - Targeting ATP docking and P35/P25 binding of CDK5 in Glioma Stem Cells using Synthetic Inhibitors
Location: Ballroom Lawn
Subhas Mukherjee – Northwestern University
Saturday, Nov 23
5:00 pm

DDIS-31 - A novel brain-permeant chemotherapeutic agent for the treatment of breast cancer leptomeningeal metastasis
Location: Ballroom Lawn
Sophia B. Chernikova, MS, PhD – Department of Neurosurgery, Stanford University
Saturday, Nov 23
5:00 pm

DDIS-35 - RelA-activity is essential for Cannabidiol-mediated cytotoxicity in an identified subset of glioblastoma
Location: Ballroom Lawn
Rainer Glass – Neurosugical Research, Department of Neurosurgery, University Hospital LMU Munich
Saturday, Nov 23
5:00 pm

DDIS-37 - Small Molecule Autophagy Activators in Growth Inhibition of Glioblastoma
Location: Ballroom Lawn
Venkata Mahidhar Yenugonda – John Wayne Cancer Institute
Drug Resistance
Friday, Nov 22
3:25 pm

DRES-08 - Clinical Significance of Hypermutation in Gliomas
Location: Grand Canyon 8-13
Keith L. Ligon – Dana-Farber Cancer Institute
Friday, Nov 22
4:45 pm

DRES-09 - Regulatory effects of the ciliary GTPase ARL13B on purine metabolism in GBM
Location: Grand Canyon 8-13
Miranda R. Saathoff – Northwestern University
Friday, Nov 22
7:34 pm

DRES-04 - Long Non-Coding RNAs in Glioblastoma Tumor Recurrence and Therapy Resistance
Location: Wildflower B
Christian T. Stackhouse – University of Alabama at Birmingham
Friday, Nov 22
8:06 pm

DRES-02 - PARylation of MGMT by PARP is required for MGMT mediated Temozolomide-induced O⁶-methylguanine repair: A novel mechanism of MGMT action
Location: Wildflower B
Dimpy Koul – MD Anderson Cancer Center
Friday, Nov 22
7:30 pm

DRES-06 - Prostaglandin E Receptor 3 mediates resistance to Tumor Treating Fields in glioblastoma cells
Location: Ballroom Lawn
Dongjiang Chen – Lilian Wells Department of Neurological Surgery, the University of Florida
Friday, Nov 22
7:30 pm

DRES-12 - Quantifying individualized ABT-414 sensitivity and blood-brain barrier penetrance from serial imaging of patient-derived xenografts models of glioblastoma
Location: Ballroom Lawn
Javier C. Urcuyo – Mayo Clinic
Saturday, Nov 23
5:00 pm

DRES-01 - Efficacy of EGFR plus TNF inhibition in a preclinical model of glioblastoma
Location: Ballroom Lawn
Gao Guo, PhD – UT Southwestern
Saturday, Nov 23
5:00 pm

DRES-03 - PARP inhibitor, inhibition of homologous recombination, or dianhydrodulcitol can overcome temozolomide-resistance in glioma cells.
Location: Ballroom Lawn
Shigeo Ohba – Fujita Health University
Saturday, Nov 23
5:00 pm

DRES-05 - Predictors of sensitivity to combined temozolomide and PARP inhibitor in glioma
Location: Ballroom Lawn
Hiroaki Nagashima – Massachusetts General Hospital
Saturday, Nov 23
5:00 pm

DRES-07 - TMZ-LEV- IFN cocktail regimen significantly inhibited the growth of glioma in vivo
Location: Ballroom Lawn
Zhong-ping Chen – Sun Yat-sen University Cancer Centre
Saturday, Nov 23
5:00 pm

DRES-13 - Dual kinase inhibition to combat EGFR-inhibitor resistance in glioblastoma
Location: Ballroom Lawn
C. Ryan Miller – University of Alabama at Birmingham
Sunday, Nov 24
9:15 am

DRES-10 - Temozolomide-Associated Hypermutation Detected with a Gene Panel Signature Improves Immune Response in Glioblastoma
Location: Grand Canyon 1-6
Bassam S. Abdulkarim – McGill University
Epidemiology
Friday, Nov 22
1:30 pm

EPID-25 - How many patients in a real world glioblastoma population meet eligibility criteria in clinical trials?
Location: Grand Canyon 8-13
Erlend Skaga – Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Norway
Friday, Nov 22
2:40 pm

EPID-19 - Shared genomic architecture of glioma and neuro-cognitive and neuro-psychiatric traits revealed by LD-Score regression
Location: Grand Canyon 8-13
Kyle M. Walsh – Duke University School of Medicine
Friday, Nov 22
7:30 pm

EPID-03 - Histology-specific brain tumor incidence and survival varies by sex
Location: Ballroom Lawn
Jill S. Barnholtz-Sloan – Case Comprehensive Cancer Center and Cleveland Institute for Computational Biology Case Western Reserve University School of Medicine
Friday, Nov 22
7:30 pm

EPID-04 - Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States
Location: Ballroom Lawn
Jill S. Barnholtz-Sloan – Case Comprehensive Cancer Center and Cleveland Institute for Computational Biology Case Western Reserve University School of Medicine
Friday, Nov 22
7:30 pm

EPID-08 - Types of brain cancer in the central Texas military population
Location: Ballroom Lawn
Jennifer H. Murillo – Baylor Scott & White
Friday, Nov 22
7:30 pm

EPID-10 - Venous thromboembolic events in glioblastoma patients: an epidemiological view
Location: Ballroom Lawn
Dorothee Gramatzki – Department of Neurology, University Hospital and University of Zurich
Friday, Nov 22
7:30 pm

EPID-12 - Impact of race and geographic location on IDH mutations and glioblastoma survival
Location: Ballroom Lawn
Yoshua Esquenazi – Mischer Neuroscience Institute / Department of Neurosurgery, University of Texas Health Science Center.
Friday, Nov 22
7:30 pm

EPID-14 - Occurrence of systemic cancer in patients with oligodendrogliomas: population characterization and complications
Location: Ballroom Lawn
Erika Horta – Henry Ford Hospital
Friday, Nov 22
7:30 pm

EPID-18 - National Trends in the Use of Targeted and Immunotherapy in the Up Front Management of Glioblastoma
Location: Ballroom Lawn
Rodney Wegner – AHN Cancer Institute
Friday, Nov 22
7:30 pm

EPID-20 - Trends in glioblastoma outcomes over time, geographic location and type of intervention
Location: Ballroom Lawn
Lina C. Marenco-Hillembrand – Mayo Clinic
Friday, Nov 22
7:30 pm

EPID-22 - Newly-diagnosed brain tumors in pediatric patients: Epidemiology in the United States
Location: Ballroom Lawn
Bryan Iorgulescu – Dana-Farber Cancer Institute
Friday, Nov 22
7:30 pm

EPID-24 - Does the location matter? Characterization of the anatomic locations, molecular profiles, and clinical features of gliomas.
Location: Ballroom Lawn
Christopher P. Mackintosh – Mayo Clinic School of Medicine
Friday, Nov 22
7:30 pm

EPID-26 - Sex-Specific Glioma Molecular Signatures
Location: Ballroom Lawn
Elizabeth B. Claus – Yale University
Friday, Nov 22
7:30 pm

EPID-28 - What do patterns of “unclassified” brain tumors tell us about incidence rates of non-malignant brain tumors in Canada?
Location: Ballroom Lawn
Joseph Megyesi – Western University
Friday, Nov 22
7:30 pm

EPID-30 - A Twitter-Based Network Analysis of Brain Tumor Social Media (#BTSM)
Location: Ballroom Lawn
Josemari Feliciano – Yale Univerisity
Friday, Nov 22
7:30 pm

EPID-32 - Is there any evidence of reporting and citation bias among completed phase III interventional brain tumor trials?
Location: Ballroom Lawn
Appaji Rayi, MBBS – The Ohio State University Wexner Medical Center
Saturday, Nov 23
5:08 pm

EPID-06 - Immune-related plasma biomarkers in glioblastoma
Location: Wildflower B
Camilla Bjørnbak Holst – Department of Radiation Biology, Rigshospitalet, Copenhagen University Hospital, Denmark
Saturday, Nov 23
5:12 pm

EPID-16 - Comparative Analysis of Overall Survival and Adverse Events by Adjuvant Treatment Modalities in Elderly Patients with Glioblastoma Using the SEER-Medicare Database
Location: Wildflower B
Jay-Jiguang Zhu – University of Texas Health Science Center
Saturday, Nov 23
5:00 pm

EPID-01 - Sex difference in expression of iron-related genes and survival in glioblastoma patients
Location: Ballroom Lawn
Sang Y. Lee – The Pennsylvania State University College of Medicine
Saturday, Nov 23
5:00 pm

EPID-02 - Height and the risk of meningioma
Location: Ballroom Lawn
Shlomit Yust-Katz – rabin medical center
Saturday, Nov 23
5:00 pm

EPID-05 - Prediagnostic symptoms and signs of adult glioma: the patients’ view
Location: Ballroom Lawn
Marijke Coomans – Leiden University Medical Center
Saturday, Nov 23
5:00 pm

EPID-07 - Hematological adverse events in glioblastoma patients treated with temozolomide
Location: Ballroom Lawn
John Villano – University of Kentucky
Saturday, Nov 23
5:00 pm

EPID-09 - Prognostic factors in adult patients with primary intracranial ependymomas: a population-based study
Location: Ballroom Lawn
Helen Yang – University of Toronto
Saturday, Nov 23
5:00 pm

EPID-11 - Occurrence of systemic cancer in patients with glioblastoma: population characterization and complications
Location: Ballroom Lawn
Erika Horta – Henry Ford Hospital
Saturday, Nov 23
5:00 pm

EPID-13 - Identification of prognostic markers in a cohort of consecutive non-selected glioblastoma patients receiving standard therapy
Location: Ballroom Lawn
Signe Regner Michaelsen – Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark
Saturday, Nov 23
5:00 pm

EPID-15 - Guidelines for the optimal use of social media for neuro-oncologists
Location: Ballroom Lawn
Nima Hamidi – Arizona college of osteopathic medicine
Saturday, Nov 23
5:00 pm

EPID-17 - Analysis of the use of Bevacizumab for the treatment of glioblastoma in the United States
Location: Ballroom Lawn
John Villano – University of Kentucky
Saturday, Nov 23
5:00 pm

EPID-21 - The national spectrum of newly-diagnosed brain tumors in adult patients varies significantly by patient demographics
Location: Ballroom Lawn
Bryan Iorgulescu – Dana-Farber Cancer Institute
Saturday, Nov 23
5:00 pm

EPID-23 - Pursuit of an international language of glioma research: common data elements for the longitudinal study of adult malignant glioma
Location: Ballroom Lawn
Laila M. Poisson – Henry Ford Health System
Saturday, Nov 23
5:00 pm

EPID-27 - Occurrence of systemic cancer in patients with astrocytoma: population characterization and complications
Location: Ballroom Lawn
Erika Horta – Henry Ford Hospital
Saturday, Nov 23
5:00 pm

EPID-29 - The influence of socioeconomic factors and cancer care received at different facilities on outcome in patients with glioblastoma.
Location: Ballroom Lawn
Terry Li – New York University School of Medicine
Saturday, Nov 23
5:00 pm

EPID-31 - Efficient study of surgically treated meningioma through clinical data standardization
Location: Ballroom Lawn
Karolyn H. Au, MD, MSc, FRCSC – University of Alberta
Saturday, Nov 23
5:00 pm

EPID-33 - Gender-specific probabilistic atlases of glioblastoma reveal impact of tumor location on progression free survival
Location: Ballroom Lawn
Pallavi Tiwari – Case Western Reserve University
Saturday, Nov 23
5:00 pm

EPID-34 - Geodemographic Classification of Glioblastoma Risk in a Rural Hospital System: Relationship to tumor incidence and overall survival
Location: Ballroom Lawn
Ali Haadi – Geisinger Commonwealth School of Medicine
Experimental Therapeutics
Friday, Nov 22
3:15 pm

EXTH-27 - Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL
Location: Grand Canyon 8-13
Candelaria Gomez-Manzano – MD Anderson Cancer Center
Friday, Nov 22
4:05 pm

EXTH-47 - Therapeutic reversal of prenatal pontine ID1 signaling in DIPG
Location: Grand Canyon 8-13
Vivekanand Yadav – Michigan Medicine
Friday, Nov 22
4:35 pm

EXTH-11 - Treatment with Delta-24-RGDOX of subcutaneous tumors results in abscopal effect eradicating intracranial melanomas
Location: Grand Canyon 8-13
Juan Fueyo – MD Anderson Cancer Center
Friday, Nov 22
4:40 pm

EXTH-32 - Development of EphA3 Directed Chimeric Antigen Receptor T Cell Therapy for the Treatment of Glioblastoma Multiforme
Location: Grand Canyon 8-13
Michael Ruff, MD – Mayo Clinic
Friday, Nov 22
4:50 pm

EXTH-58 - Inhibition of DNA topoisomerase 1 and poly(ADP-ribose) polymerase synergistically induces cell death in glioblastoma with PTEN loss
Location: Grand Canyon 8-13
Madison Butler – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Friday, Nov 22
7:38 pm

EXTH-33 - Receptor pharmacology of ONC201: The first bitopic DRD2 antagonist for clinical neuro-oncology
Location: Wildflower B
Joshua E. Allen – Oncoceutics, Inc.
Friday, Nov 22
7:42 pm

EXTH-62 - Stem cell delivery of oncolytic adenovirus DNX-2401 following surgical resection for the treatment of glioblastoma
Location: Wildflower B
Sricharan Gopakumar – MD Anderson Cancer Center
Friday, Nov 22
7:54 pm

EXTH-39 - Bench to Bedside Neuro-Oncology: Advocating For a Clinically Relevant Strategy
Location: Wildflower B
Samer G. Zammar – Penn State Health
Friday, Nov 22
7:58 pm

EXTH-49 - Therapeutic efficacy of engineered, hydrogel encapsulated bimodal MSC in glioblastoma stratified on cell surface receptor expression
Location: Wildflower B
Deepak Bhere – Brigham and Women's Hospital
Friday, Nov 22
8:22 pm

EXTH-14 - Pulsed electric fields for the treatment of brain tumors
Location: Wildflower B
Yael Mardor – Sheba medica center
Friday, Nov 22
8:26 pm

EXTH-12 - Radiation enhances melanoma response to immunotherapy and synergizes with benzodiazepines to promote anti-tumor activity
Location: Wildflower B
Soma Sengupta – University of Cincinnati College of Medicine; Gardner Neuroscience Institute
Friday, Nov 22
7:30 pm

EXTH-02 - The blood brain barrier (BBB) permeability is altered by Tumor Treating Fields (TTFields) in vivo
Location: Ballroom Lawn
Ellina Schulz – University of Würzburg
Friday, Nov 22
7:30 pm

EXTH-04 - Blockade of NRF2/glutathione metabolism as a synthetic lethality approach for IDH1-mutated glioma
Location: Ballroom Lawn
Chunzhang Yang, PhD – National Cancer Institute
Friday, Nov 22
7:30 pm

EXTH-06 - Down-regulation of PD-L1 via FKBP5 lowered by a cyclooxygenase-2 inhibitor in GSCs and GBM cells may be attributable to enhance antitumor effects of immunotherapy
Location: Ballroom Lawn
Izumi Yamaguchi – Tokushima University Graduate School of Biomedical Sciences
Friday, Nov 22
7:30 pm

EXTH-08 - Replacement of microglia by brain-engrafted macrophages prevents memory deficits after therapeutic whole-brain irradiation
Location: Ballroom Lawn
Xi Feng – University of California, San Francisco, Department of Physical Therapy and Rehabilitation Science, Department of Neurological Surgery
Friday, Nov 22
7:30 pm

EXTH-10 - The Activation and Sensitization of Glioblastoma Cells via Cold Atmospheric Plasma Treatment
Location: Ballroom Lawn
Jonathan H. Sherman – George Washington University
Friday, Nov 22
7:30 pm

EXTH-16 - Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells for Glioblastoma Immunotherapy
Location: Ballroom Lawn
Shuyang He – Celularity Inc
Friday, Nov 22
7:30 pm

EXTH-18 - Peptide nano-structures enhance pediatric brain tumor chemotherapeutic efficacy
Location: Ballroom Lawn
Guifa XI – Lurie Children's Hospital of Chicago
Friday, Nov 22
7:30 pm

EXTH-20 - Hyperpolarized [2-¹³C] pyruvate to [5-¹³C] glutamate as biomarkers of IDH1 mutant glioma response to temozolomide therapy
Location: Ballroom Lawn
Elavarasan Subramani – Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America
Friday, Nov 22
7:30 pm

EXTH-22 - Enhanced drug delivery and circulation with the Neurapheresis™ system for the treatment of leptomeningeal metastases
Location: Ballroom Lawn
Choiselle Marius – Duke University Department of Neurosurgery
Friday, Nov 22
7:30 pm

EXTH-28 - Targeted PolyGIONs engineered with surface miRNAs for combined multimodality imaging and enhancement of temozolomide treatment: A novel intranasally-delivered theranostic strategy against glioblastoma
Location: Ballroom Lawn
Tarik F. Massoud – Stanford University School of Medicine
Friday, Nov 22
7:30 pm

EXTH-30 - Preceding p53 stabilization using doxorubicin augments PRIMA-1-mediated p53 refolding and increased cellular apoptosis: Evaluation of a sequential combination therapy against glioblastoma
Location: Ballroom Lawn
Tarik F. Massoud – Stanford University School of Medicine
Friday, Nov 22
7:30 pm

EXTH-34 - In vitro tumor treating fields (TTFields) applied prior to radiation enhances the response to radiation in patient-derived glioblastoma cell lines
Location: Ballroom Lawn
Sandeep Mittal – UT MD Anderson Cancer Center, Houston, Texas
Friday, Nov 22
7:30 pm

EXTH-36 - PI3K inhibition in conjunction with the ketogenic diet reduces growth and neuroinflammation in pediatric high-grade glioma
Location: Ballroom Lawn
Evan Noch – Weill Cornell Medicine
Friday, Nov 22
7:30 pm

EXTH-38 - Engineered exosomes for therapeutic gene delivery in brain tumors
Location: Ballroom Lawn
Malcolm F. McDonald – Baylor College of Medicine
Friday, Nov 22
7:30 pm

EXTH-42 - Quantitative Biodistribution of Adoptively Transferred T Cells in Brain Tumor-Bearing Mice
Location: Ballroom Lawn
Lan Hoang-Minh – University of Florida
Friday, Nov 22
7:30 pm

EXTH-44 - Inhibition of MerTK activates glioblastoma-associated macrophages and induces tumor cell death in glioma microenvironment
Location: Ballroom Lawn
Yu-Ting Su – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Friday, Nov 22
7:30 pm

EXTH-46 - Alisertib potentiates the effect of cabozantinib and vandetanib against glioblastoma cells
Location: Ballroom Lawn
Brian J. Williams – University of Louisville
Friday, Nov 22
7:30 pm

EXTH-48 - Galectin-1 Inhibition Sensitizes Radiation Treatment in a Pre-clinical model of Glioblastoma
Location: Ballroom Lawn
Fraser Henderson, Jr., MD – Medical University of South Carolina
Friday, Nov 22
7:30 pm

EXTH-50 - Thioredoxin Reductase1 and MGMT synthetic lethality enhances cytotoxicity of PRIMA-1MET(APR-246) and Auranofin in glioblastoma
Location: Ballroom Lawn
Siham Sabri – McGill University
Friday, Nov 22
7:30 pm

EXTH-52 - Co-targeting oncostatin M receptor using monoclonal antibodies in combination with present standards of care for glioblastoma
Location: Ballroom Lawn
Audrey Burban – McGill University, Lady Davis Institute for Medical Research
Friday, Nov 22
7:30 pm

EXTH-56 - Medulloblastomas respond to CDK4/6 inhibition with nanoparticle-delivered palbociclib with altered S-phase progression
Location: Ballroom Lawn
Taylor Y. Dismuke – Univ. of North Carolina-Chapel Hill
Friday, Nov 22
7:30 pm

EXTH-60 - Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse intrinsic pontine glioma
Location: Ballroom Lawn
Takahiro Sasaki – Northwestern University
Friday, Nov 22
7:30 pm

EXTH-64 - Evaluation the combination effect of radiation and focused ultrasound in treatment of brain tumor model animals
Location: Ballroom Lawn
Chiungyin Huang – Department of Medicine, Chang Gung University
Friday, Nov 22
7:30 pm

EXTH-68 - Intranasal Delivery of Drug-Loaded Liposomes Sensitizes Tumors To Irradiation In Syngeneic Model Of Glioma.
Location: Ballroom Lawn
Irina Balyasnikova – Northwestern University
Friday, Nov 22
7:30 pm

EXTH-70 - Enhancement of antitumor activity by using 5-ALA–mediated sonodynamic therapy to induce apoptosis and necrosis in a mouse glioma model
Location: Ballroom Lawn
Satoshi Suehiro – Department of Neurosurgery, Ehime University Graduate School of Medicine
Friday, Nov 22
7:30 pm

EXTH-72 - Manzamine A-derived compounds as potential anti-brain tumor agents and it mechanism study
Location: Ballroom Lawn
Pin-Yuan Chen – Chang Gung Memorial Hospital, Keelung
Saturday, Nov 23
5:20 pm

EXTH-54 - Multivalent targeted proteins for glioblastoma treatment
Location: Wildflower B
Puja Sharma – Wake Forest Baptist Medical Center Comprehensive Cancer Center
Saturday, Nov 23
5:24 pm

EXTH-15 - Increasing the trafficking of dendritic cells via CXC chemokine signaling pathway leads to improved anti-tumor efficacy of dendritic cell vaccines
Location: Wildflower B
Farhad Dastmalchi – Preston A. Wells, Jr. Center for Brain Tumor Therapy, UF Brain Tumor Immunotherapy Program, University of Florida
Saturday, Nov 23
5:00 pm

EXTH-01 - A syngenic mouse model to study the efficacy of ketogenic diet in high grade gliomas
Location: Ballroom Lawn
Emilio Ciusani – Fondazione IRCCS Istituto Neurologico C. Besta
Saturday, Nov 23
5:00 pm

EXTH-03 - Triptolide, a novel therapeutic agent for IDH1-mutated glioma
Location: Ballroom Lawn
Yang Liu – National Cancer Institute
Saturday, Nov 23
5:00 pm

EXTH-05 - Therapeutic implications of TTFields induced DNA damage and replication stress in novel combinations for cancer treatment
Location: Ballroom Lawn
Narasimha Kumar Karanam – UT Southwestern Medical Center
Saturday, Nov 23
5:00 pm

EXTH-07 - Optimization of targeting ELTD1 in Glioblastoma using a molecular targeting approach
Location: Ballroom Lawn
Rheal Towner – Oklahoma Medical Research Foundation
Saturday, Nov 23
5:00 pm

EXTH-09 - First-in-human dosing considerations of a bispecific antibody for treating glioblastoma
Location: Ballroom Lawn
Teilo H. Schaller – Duke University Medical School
Saturday, Nov 23
5:00 pm

EXTH-13 - Neurosurgical delivery of the poly ADP ribose polymerase-1 inhibitor olaparib from a thermo-responsive biodegradable paste potentiates radiotherapy and prolongs survival in high-grade glioma
Location: Ballroom Lawn
Ruman Rahman – University of Nottingham
Saturday, Nov 23
5:00 pm

EXTH-17 - Treatment of malignant gliomas with drug-loaded microbubbles: conception of a promising future therapeutic strategy
Location: Ballroom Lawn
Ellina Schulz – University of Würzburg
Saturday, Nov 23
5:00 pm

EXTH-19 - Ibrutinib modulates blood-brain barrier integrity to enhance chemotherapy permeability
Location: Ballroom Lawn
Amelie Vezina – National Institutes of Health
Saturday, Nov 23
5:00 pm

EXTH-21 - Differential protein expression levels of ABC and solute carrier transporters at the blood-brain barrier of human brain and glioblastoma
Location: Ballroom Lawn
Jing Li – The University of Texas MD Anderson Cancer Center
Saturday, Nov 23
5:00 pm

EXTH-23 - Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
Location: Ballroom Lawn
Jihwan Yoo – Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine
Saturday, Nov 23
5:00 pm

EXTH-25 - A mechanically-engineered spray to increase brain penetration of chemotherapeutic nanoparticles in the treatment of high grade gliomas
Location: Ballroom Lawn
Phoebe C. McCrorie – University of Nottingham
Saturday, Nov 23
5:00 pm

EXTH-29 - Galectin-3 as a Potential Therapeutic Target in Recurrent Atypical and Malignant Meningioma
Location: Ballroom Lawn
Arabinda Das – Medical University of South Carolina
Saturday, Nov 23
5:00 pm

EXTH-31 - Combination of tumor treating fields (TTFields) and paclitaxel produces additive reductions in proliferation and clonogenicity in patient-derived metastatic non-small cell lung cancer (NSCLC) cells
Location: Ballroom Lawn
Sharon Michelhaugh – Virginia Tech
Saturday, Nov 23
5:00 pm

EXTH-35 - Laser Interstitial Thermal Therapy increases Blood-Brain Barrier and Blood-Tumor Barrier Permeability in a Mouse Model of Glioblastoma
Location: Ballroom Lawn
Mounica R. Paturu – Washington University in St. Louis School of Medicine
Saturday, Nov 23
5:00 pm

EXTH-37 - A novel Transducer array layout for delivering Tumor Treating Fields to the spine
Location: Ballroom Lawn
Ze'ev Bomzon – Novocure ltd.
Saturday, Nov 23
5:00 pm

EXTH-45 - Therapeutic efficacy of mutant isocitrate dehydrogenase 1 (IDH1) inhibitor SYC-435 with standard therapy in patient-derived IDH1 mutant glioma xenograft mouse models
Location: Ballroom Lawn
Yuchen Du – Texas Children's Cancer Center
Saturday, Nov 23
5:00 pm

EXTH-51 - Genetically Stable Poliovirus Vector Platform for DIPG Immunotherapy
Location: Ballroom Lawn
Matthias Gromeier – Duke University Medical Center
Saturday, Nov 23
5:00 pm

EXTH-53 - Tumor Treating Fields leads to changes in membrane permeability and increased penetration by anti-glioma drugs
Location: Ballroom Lawn
Edwin Chang – Stanford University
Saturday, Nov 23
5:00 pm

EXTH-55 - Temozolomide-resistant glioma cells are sensitive to chloroethylating nitrosourea compounds in combination with ATR inhibitors
Location: Ballroom Lawn
Christopher Jackson – Columbia University College of Physicians and Surgeons
Saturday, Nov 23
5:00 pm

EXTH-57 - Preclinical combination of ONC201 with radiotherapy or Temozolomide in GBM, DIPG and ATRT cell lines results in dopamine receptor antagonism, ATF4 induction and cell death
Location: Ballroom Lawn
Wafik S. El-Deiry – Brown University
Saturday, Nov 23
5:00 pm

EXTH-61 - Celecoxib Improves Outcome of Patients Treated with Tumor Treating Fields
Location: Ballroom Lawn
Kenneth Swanson – Beth Israel Deaconess Medical Center
Saturday, Nov 23
5:00 pm

EXTH-63 - Liposomal delivery of ferritin heavy chain (FTH1) siRNA results in increased radiation sensitivity in patient derived glioma initiating cells
Location: Ballroom Lawn
Bhavyata Pandya – Penn State College of Medicine
Saturday, Nov 23
5:00 pm

EXTH-65 - Plasma and cerebrospinal fluid pharmacokinetics comparison of BRAF and MEK inhibitors following single and extended administration in a pre-clinical non-human primate model
Location: Ballroom Lawn
Cynthia M. Lester McCully – NCI
Saturday, Nov 23
5:00 pm

EXTH-67 - Identification and development of neural ECM-binding lamprey antibodies (variable lymphocyte receptors) that target glioblastoma
Location: Ballroom Lawn
Benjamin J. Umlauf – University of Wisconsin
Saturday, Nov 23
5:00 pm

EXTH-69 - Nanotherapeutics for neurosurgically-applied drug delivery
Location: Ballroom Lawn
Catherine E. Vasey – University of Nottingham
Saturday, Nov 23
5:00 pm

EXTH-71 - IND-enabling characterization of ONC206 as the next bitopic DRD2 antagonist for neuro-oncology
Location: Ballroom Lawn
Varun V. Prabhu, PhD – Oncoceutics, Inc.
Genetics and Epigenetics
Friday, Nov 22
3:35 pm

GENE-22 - Genome-wide methylation profiling of glioblastoma extracellular vesicle DNA allows tumor classification
Location: Grand Canyon 7
Franz Ricklefs – Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
Friday, Nov 22
4:15 pm

GENE-57 - COMPARATIVE MOLECULAR LIFE HISTORY OF SPONTANEOUS CANINE AND HUMAN GLIOMA
Location: Grand Canyon 7
Samirkumar B. Amin, MBBS, PhD – The Jackson Laboratory for Genomic Medicine
Friday, Nov 22
7:30 pm

GENE-06 - Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma
Location: Ballroom Lawn
Sojin Kim – Seoul national University Hospital
Friday, Nov 22
7:30 pm

GENE-08 - Secondary glioblastoma, IDH-wildtype arising in diffuse astrocytoma, IDH-mutant: a case report
Location: Ballroom Lawn
Kyu Sang Lee – Seoul National University Bundang Hospital
Friday, Nov 22
7:30 pm

GENE-10 - A simple and efficient method for generating multi-allelic insertion-deletion mutations and precise deletions in primary human cell cultures
Location: Ballroom Lawn
Megan Kufeld – Fred Hutchinson Cancer Research Center
Friday, Nov 22
7:30 pm

GENE-12 - Analysis of failure patterns in malignant glioma: exploring the genetic landscape of pattern of failure
Location: Ballroom Lawn
Seung Won Choi – Samsung Medical Center
Friday, Nov 22
7:30 pm

GENE-14 - BMP4 induces to asymmetric cell division in human glioma stem-like cells
Location: Ballroom Lawn
Tatsuya Abe – Saga University
Friday, Nov 22
7:30 pm

GENE-16 - Next generation sequencing identifies IDH-1, ATRX, TP53 mutation and MYCN amplification in glioblastoma with extensive subarachnoid spread: a case report
Location: Ballroom Lawn
Kyu Sang Lee – Seoul National University Bundang Hospital
Friday, Nov 22
7:30 pm

GENE-18 - Transcriptome-wide Analysis using Nanopore Third Generation Sequencing in a Rat Glioblastoma Model: Proof of Principle
Location: Ballroom Lawn
Analiz Rodriguez, MD, PhD – University of Arkansas for Medical Sciences
Friday, Nov 22
7:30 pm

GENE-20 - Identifying potential genes and mechanisms driving IDH-mutant glioma progression and recurrence through RNA-sequencing
Location: Ballroom Lawn
Angela Cho – Bill Walsh Translational Cancer Research Laboratory, The University of Sydney Northern Clinical School & Northern Sydney Local Health District Research (Kolling Institute of Medical Research)
Friday, Nov 22
7:30 pm

GENE-24 - DNA Methylation Signatures Detected in a Serum-based Liquid Biopsy Distinguish Functional and Invasiveness Features in Pituitary Adenomas
Location: Ballroom Lawn
Michael Wells – Henry Ford Health System
Friday, Nov 22
7:30 pm

GENE-30 - Preliminary study on whole-exome sequencing technology in the genetic analysis of pediatric patients with gliomas
Location: Ballroom Lawn
Mingyao Lai – Guangdong Sanjiu Brain Hospital
Friday, Nov 22
7:30 pm

GENE-38 - IDH1^MUT induces N⁶-methyladenosine (m6A) RNA hypermethylation via D-2-HG in glioma
Location: Ballroom Lawn
Sean T. Pianka – David Geffen School of Medicine, UCLA
Friday, Nov 22
7:30 pm

GENE-42 - Exome sequencing analysis to identify possible genomic drivers of metastatic invasion into the spine
Location: Ballroom Lawn
Alexandra Calinescu – University of Michigan
Friday, Nov 22
7:30 pm

GENE-46 - XAF1 drives differential plasticity towards adaptive resistance between MGMT-hypermethylated and MGMT-hypomethylated glioblastoma
Location: Ballroom Lawn
Qiong Wu – H. Lee Moffitt Cancer Center and Research Institute
Friday, Nov 22
7:30 pm

GENE-48 - Analysis of human brain tissue transcriptome to identify risk genes and altered molecular pathways in glioma-related seizures
Location: Ballroom Lawn
Anteneh M. Feyissa – Mayo Clinic
Friday, Nov 22
7:30 pm

GENE-52 - Analysis of recurrent mutations within cancers reveals patterns of directional evolution in brain tumors
Location: Ballroom Lawn
Bart Westerman – Amsterdam UMC, Cancer Center Amsterdam
Friday, Nov 22
7:30 pm

GENE-54 - Investigating the roles of NCOR1 and NCOR2 in metastatic invasion into the spine.
Location: Ballroom Lawn
Zain Sultan – University of Michigan
Friday, Nov 22
7:30 pm

GENE-58 - Active transcription start sites of meningioma samples associated with risk of recurrence
Location: Ballroom Lawn
Tathiane Malta – University of São Paulo
Friday, Nov 22
7:30 pm

GENE-60 - The Epitranscriptomic Code in LGG: Metabolically reprogrammed IDH-mutant gliomas alter tRNA modification landscape
Location: Ballroom Lawn
Chantal Scheepbouwer – Amsterdam UMC/VUmc, Department of Neurosurgery, Neuro-Oncology Research Group
Saturday, Nov 23
2:20 pm

GENE-01 - The mutational landscape of primary chordomas and their sensitive detection in plasma ctDNA by multiple next generation sequencing technologies
Location: Grand Canyon 1-6
Austin Mattox, MPH – Johns Hopkins School of Medicine
Saturday, Nov 23
5:04 pm

GENE-55 - Gene expression signature associated with aggressive glioblastoma growth is enriched in chromatin modification and stemness transcriptional regulation programs
Location: Wildflower C
Ana C. deCarvalho, PhD – Henry Ford Hospital Wayne State University
Saturday, Nov 23
5:08 pm

GENE-25 - GWAS by Molecular Subtype Identified Novel Risk Loci for Adult Diffuse Glioma
Location: Wildflower C
Jeanette E. Eckel-Passow – Mayo Clinic
Saturday, Nov 23
5:32 pm

GENE-56 - Meningioma Genomic Subgroup as a Predictor of Post-Operative Patient Outcomes: Implications for Treatment and Follow-up
Location: Wildflower C
Mark W. Youngblood – Department of Neurosurgery, Yale School of Medicine
Saturday, Nov 23
5:36 pm

GENE-62 - Identification of FGFR4 p.G388R Variant in Cerebellar Hemangioblastomas
Location: Wildflower C
David Zagzag – New York University Langone Health
Saturday, Nov 23
5:44 pm

GENE-04 - The oncogenic functions of YAP1-gene fusions can be inhibited by disruption of YAP1-TEAD interaction.
Location: Wildflower C
Frank Szulzewsky – Fred Hutchsinson Cancer Research Center
Saturday, Nov 23
5:56 pm

GENE-44 - Brd4 deletion leads to cerebellar deficits and ataxia
Location: Wildflower C
Nagi Ayad – university of miami
Saturday, Nov 23
5:00 pm

GENE-03 - Specific signatures of microRNA in cerebrospinal fluid of patients with primary brain tumors and metastases.
Location: Ballroom Lawn
Radim Jancalek – Department of Neurosurgery, St Anne's University Hospital, Brno, Czech Republic
Saturday, Nov 23
5:00 pm

GENE-07 - Influence of epigenetic modulation of the T-cell regulators expression on glioblastomas by histone 3 lysine methyltransferase or demethylase on the prognosis of the glioblastoma patients
Location: Ballroom Lawn
YOUNG ZOON KIM – SUNGKYUKWAN UNIVERSITY
Saturday, Nov 23
5:00 pm

GENE-09 - Long noncoding RNA lncHLX2-7 a putative molecular marker and a therapeutic target for Group III medulloblastoma
Location: Ballroom Lawn
Keisuke Katsushima – Johns Hopkins University
Saturday, Nov 23
5:00 pm

GENE-11 - LDScore regression identifies novel associations between glioma and auto-immune conditions
Location: Ballroom Lawn
Quinn T. Ostrom – Baylor College of Medicine
Saturday, Nov 23
5:00 pm

GENE-13 - Genomic and radiomic landscape of IDH wildtype-TERT promoter mutation in lower-grade gliomas
Location: Ballroom Lawn
Shuai Liu, MD – Beijing Tiantan Hospital
Saturday, Nov 23
5:00 pm

GENE-19 - Targeted sequencing panel (Todai OncoPanel) for various types of brain tumors
Location: Ballroom Lawn
Shunsaku Takayanagi – Department of Neurosurgery, University of Tokyo
Saturday, Nov 23
5:00 pm

GENE-21 - Role of POT1 mutation in glioma proliferation and sexual divergence of survival
Location: Ballroom Lawn
Ali Jalali – Baylor College of Medicine
Saturday, Nov 23
5:00 pm

GENE-23 - Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas
Location: Ballroom Lawn
Franz Ricklefs – Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
Saturday, Nov 23
5:00 pm

GENE-27 - Meningioma Recurrence: Role of M1/M2 Tumour-associated Macrophage Infiltration
Location: Ballroom Lawn
Abdulrahman Albakr, MD – University of Calgary
Saturday, Nov 23
5:00 pm

GENE-29 - Increased Copy Number Burden (CNB) is Associated with Grade in IDH-mutant, 1p/19q-codeleted Oligodendrogliomas.
Location: Ballroom Lawn
Desmond A. Brown, MD, PhD – Mayo Clinic
Saturday, Nov 23
5:00 pm

GENE-33 - Integrated glioma diagnostics using targeted next-generation sequencing
Location: Ballroom Lawn
Jeanette Krogh Petersen – Department of Pathology, Odense University Hospital
Saturday, Nov 23
5:00 pm

GENE-35 - MGMT promoter methylation in newly diagnosed LGG as a potential biomarker for TMZ-associated hypermutation at recurrence
Location: Ballroom Lawn
Radhika Mathur, PhD – University of California San Francisco
Saturday, Nov 23
5:00 pm

GENE-49 - RNA processing genes characterize RNA splicing and further stratify lower-grade glioma
Location: Ballroom Lawn
Rui-Chao Chai – Beijing Neurosurgical Institute
Saturday, Nov 23
5:00 pm

GENE-51 - Role of Tumor Endothelial Marker 8 (TEM8) in primary and recurrent Glioblastoma.
Location: Ballroom Lawn
Paramita Kundu – Indian Institute of Science, Bangalore, India.
Saturday, Nov 23
5:00 pm

GENE-59 - Not all p53 mutations are created equal: A murine astrocyte model for high-throughput functional assessment of p53 missense mutations
Location: Ballroom Lawn
Nathan Rockwell – Washington University School of Medicine
Saturday, Nov 23
5:00 pm

GENE-61 - Methylation-based liquid biopsy of meningioma primary and recurrent samples
Location: Ballroom Lawn
Thais Sarraf Sabedot, PhD – HENRY FORD Health System
Saturday, Nov 23
5:00 pm

GENE-63 - Genomic characterization of human brain metastases identifies novel drivers of lung adenocarcinoma progression
Location: Ballroom Lawn
Naema Nayyar – Massachusetts General Hospital
Sunday, Nov 24
8:45 am

GENE-02 - Establishing personalized treatment options for recurrent high-grade gliomas
Location: Grand Canyon 8-13
Ann-Christin Hau – NorLux Neuro-Oncology Laboratory, Luxembourg Institute of Health
Sunday, Nov 24
8:55 am

GENE-28 - LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
Location: Grand Canyon 8-13
Floris Barthel – The Jackson Laboratory for Genomic Medicine
Sunday, Nov 24
9:05 am

GENE-17 - ATRX loss in glioma results in epigenetic dysregulation of the G2/M checkpoint and sensitivity to ATM inhibition
Location: Grand Canyon 8-13
Carl J. Koschmann – Michigan Medicine
Sunday, Nov 24
9:25 am

GENE-15 - Targeting of ependymoma as informed by oncogenic 3D genome organization
Location: Grand Canyon 8-13
Lukas Chavez – UC San Diego
Sunday, Nov 24
9:35 am

GENE-26 - Host genetic variations in macrophage migration inhibitor factor confer worse prognosis in glioblastoma
Location: Grand Canyon 8-13
Balint Otvos – Cleveland Clinic Foundation
Sunday, Nov 24
9:40 am

GENE-36 - Integrating transcriptomics and kinomics identifies synergistic drug combinations for glioblastoma treatment
Location: Grand Canyon 8-13
Anna Jermakowicz – University of Miami
Sunday, Nov 24
9:45 am

GENE-39 - CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma
Location: Grand Canyon 8-13
Daniel A. Lim, MD, PhD – University of California, San Francisco
Sunday, Nov 24
9:50 am

GENE-41 - Understanding the differences in adolescent and young adult (AYA) gliomas and older adult (OA) gliomas based on functional molecular subgroups
Location: Grand Canyon 8-13
Catherine S. Bi – Georgetown University School of Medicine
Sunday, Nov 24
9:55 am

GENE-47 - A 3D Atlas to evaluate the spatial patterning of genetic alterations and tumor cell states in glioma
Location: Grand Canyon 8-13
Stephanie Hilz, PhD – Department of Neurological Surgery, University of California, San Francisco
Sunday, Nov 24
10:05 am

GENE-50 - SWI/SNF complex heterogeneity relates with polyphenotypic differentiation, prognosis and immune response in rhabdoid tumors
Location: Grand Canyon 8-13
Sriram Venneti – University of Michigan
Sunday, Nov 24
10:50 am

GENE-40 - Characterizing epigenetic intratumoral heterogeneity in glioma using single-cell bisulfite sequencing
Location: Grand Canyon 8-13
Kevin C. Johnson – The Jackson Laboratory for Genomic Medicine
Sunday, Nov 24
11:00 am

GENE-37 - Vestibular schwannoma is comprised of neural crest and immune subgroups
Location: Grand Canyon 8-13
Stephen T. Magill, MD, PhD – University of California, San Francisco
Sunday, Nov 24
11:10 am

GENE-45 - Dissecting the drivers of adult H3K27M-gliomas at the single-cell level
Location: Grand Canyon 8-13
Ilon Liu – Dana-Farber Cancer Institute
Sunday, Nov 24
11:20 am

GENE-32 - Synthetic lethal interactions with IDH1R132H in glioma stem-like cells
Location: Grand Canyon 8-13
Maria Ventosa, PhD – UNIVERSITY OF MICHIGAN
Sunday, Nov 24
11:30 am

GENE-34 - Therapeutically Targeting Epigenomic and Transcriptional Dysfunction in ATRX-deficient Glioma
Location: Grand Canyon 8-13
Jason Huse – The University of Texas MD Anderson
Sunday, Nov 24
12:00 pm

GENE-43 - Targeting GABPb1L inhibits in vivo growth of TERT promoter mutant glioblastoma
Location: Grand Canyon 8-13
Alexandra M. Amen, PhD – University of California, Berkeley; University of California, San Francisco
Health Outcome Measures
Friday, Nov 22
2:05 pm

HOUT-10 - Treatment outcome in Adolescents and Young Adults (AYAs) with glioblastoma
Location: Grand Canyon 8-13
Josiah An – University of Iowa Hospitals and Clinics
Friday, Nov 22
2:10 pm

HOUT-19 - The short-term overall survival associated with single- vs. multi-agent chemotherapeutic regimens for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation
Location: Grand Canyon 8-13
Bryan Iorgulescu, MD, FCAP – Dana-Farber Cancer Institute
Friday, Nov 22
2:15 pm

HOUT-22 - Evaluating clinical impact utilizing the RANO-PRO Collaborative’s standardized priority constructs
Location: Grand Canyon 8-13
Elizabeth Vera – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Friday, Nov 22
2:35 pm

HOUT-11 - Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas
Location: Grand Canyon 8-13
Craig Horbinski – Northwestern University
Friday, Nov 22
7:38 pm

HOUT-13 - Clinical trials in Glioblastoma: learning from previous experiences towards optimal development of trial design
Location: Wildflower C
Adithya Balasubramanian – Austin Health
Friday, Nov 22
7:30 pm

HOUT-02 - Treatment patterns and outcomes for patients with newly-diagnosed glioblastoma multiforme in a US community oncology setting
Location: Ballroom Lawn
Alex Z. Fu – Bristol-Myers Squibb Company
Friday, Nov 22
7:30 pm

HOUT-04 - Association of common patient-reported immunotherapy symptomatic side effects and pseudoprogression in patients with primary central nervous system (CNS) tumors
Location: Ballroom Lawn
Yamini Vyas – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Friday, Nov 22
7:30 pm

HOUT-06 - Systemic metabolic biomarkers obtained from computed tomography (CT)-based body composition and serum glucose predict sex-specific survival in patients with glioblastoma.
Location: Ballroom Lawn
Sonika Dahiya – Washington University School of Medicine in St. Louis
Friday, Nov 22
7:30 pm

HOUT-08 - Patient and physician perspectives on lumbar puncture
Location: Ballroom Lawn
Yoshie Umemura – University of Michigan
Friday, Nov 22
7:30 pm

HOUT-12 - Return to work following awake surgery for gliomas in speech-eloquent areas
Location: Ballroom Lawn
Marie-Therese Forster – University Hospital Frankfurt
Friday, Nov 22
7:30 pm

HOUT-14 - Prognostic Impact of first Pseudoprogression on MRI In Glioblastoma, an 11 years experience from a Canadian University Center
Location: Ballroom Lawn
Elie Zeidan – CHUM
Friday, Nov 22
7:30 pm

HOUT-16 - A retrospective analysis of survival outcomes based on consolidation regimens in primary central nervous system lymphoma
Location: Ballroom Lawn
Savannah Gelhard – Huntsman Cancer Institute
Friday, Nov 22
7:30 pm

HOUT-18 - Treatment Strategies for Glioblastoma in Older Patients: Age is Just a Number
Location: Ballroom Lawn
Michael Youssef – MD Anderson Cancer Center
Friday, Nov 22
7:30 pm

HOUT-20 - Time-dependent analysis of selective serotonin reuptake inhibitor treatment on overall survival of patients with glioblastoma
Location: Ballroom Lawn
Corey Dussold – Northwestern University
Friday, Nov 22
7:30 pm

HOUT-24 - Challenges and successes in the global reimbursement of a breakthrough medical technology for treatment of glioblastoma multiforme
Location: Ballroom Lawn
Christina Proescholdt – Novocure
Friday, Nov 22
7:30 pm

HOUT-26 - Factors associated with treatment delay in central nervous system lymphoma
Location: Ballroom Lawn
Marissa Barbaro – New York Presbyterian Hospital-Columbia University Irving Medical Center
Friday, Nov 22
7:30 pm

HOUT-28 - First-line Temozolomide vs PCV for low grade gliomas : a 11 years real-world data from CHUM, University center
Location: Ballroom Lawn
Myriam Nait Ajjou – CHUM
Saturday, Nov 23
5:00 pm

HOUT-01 - Alopecia Symptom Impact Scale (ASIS): Measuring the symptoms of alopecia and their impact in patients with primary brain tumors
Location: Ballroom Lawn
Tito R. Mendoza – University of Texas MD Anderson Cancer Center
Saturday, Nov 23
5:00 pm

HOUT-03 - Clinical Outcomes of Patients with Vestibular Schwannomas: The Relevance of Tumor Size and Recurrence
Location: Ballroom Lawn
Amy Y. Zhao – Department of Genetics, Yale School of Medicine
Saturday, Nov 23
5:00 pm

HOUT-05 - Comparing outcomes of adult diffuse midline gliomas to glioblastoma (GBM) in young patients.
Location: Ballroom Lawn
Sasmit Sarangi – Beth Israel Deaconess Medical Center
Saturday, Nov 23
5:00 pm

HOUT-07 - Association between baseline body mass index (BMI) and outcomes for patients with glioblastoma
Location: Ballroom Lawn
Jessica Chew, MD – University of California San Francisco
Saturday, Nov 23
5:00 pm

HOUT-09 - Developing Ommaya clinics for leptomeningeal carcinomatosis (LMC): standardized treatment, impact on survival/neurologic disability and role for advanced practitioners.
Location: Ballroom Lawn
Erika N. Leese – Geisinger Neuroscience Institute
Saturday, Nov 23
5:00 pm

HOUT-15 - Identification and characterization of cardiac event abnormalities in patients with craniopharyngioma
Location: Ballroom Lawn
Christa Seligman – Seton Medical Center Austin
Saturday, Nov 23
5:00 pm

HOUT-17 - Utilities of rare cancers like malignant pleural mesothelioma and glioblastoma multiforme - do they compare?
Location: Ballroom Lawn
Christina Proescholdt – Novocure
Saturday, Nov 23
5:00 pm

HOUT-21 - Characteristics of Short-Term Survival in Patients with Glioblastoma: A Retrospective Analysis
Location: Ballroom Lawn
Andrew Barbour – Duke University School of Medicine
Saturday, Nov 23
5:00 pm

HOUT-23 - Adult medulloblastoma treatment impact since 2006: a Canadian University center experience
Location: Ballroom Lawn
Maria Camila Quinones – CHUM
Saturday, Nov 23
5:00 pm

HOUT-25 - Prognostic factors for prolonged length of stay and readmission following craniotomy for primary brain tumors
Location: Ballroom Lawn
NAM TRAN – Moffitt Cancer Center
Saturday, Nov 23
5:00 pm

HOUT-27 - Healthcare Resource Utilization of Leptomeningeal Carcinomatosis in the United States
Location: Ballroom Lawn
Sarah E Hodges – Duke University
Saturday, Nov 23
5:00 pm

HOUT-29 - The influence of psychiatric illness on outcome and cancer care received in patients with gliomas.
Location: Ballroom Lawn
Palak S. Patel, MBBS – New York University Langone Health
Immunology
Friday, Nov 22
4:25 pm

IMMU-47 - RNA-nanoparticle vaccines are safe and immunologically active in client-owned canines with terminal gliomas
Location: Grand Canyon 1-6
Elias J. Sayour – University of Florida
Friday, Nov 22
4:30 pm

IMMU-07 - Cellular immunotherapy to overcome temozolomide induced T cell exhaustion in glioblastoma
Location: Grand Canyon 1-6
Aida Karachi – Preston A. Wells, Jr. Center for Brain Tumor Therapy, UF Brain Tumor Immunotherapy Program, University of Florida
Friday, Nov 22
4:35 pm

IMMU-28 - Targeting Immunosuppressive Myeloid Derived Suppressor Cells via MIF/CD74 Signaling Axis to Attenuate GBM growth
Location: Grand Canyon 1-6
Tyler J. Alban – Cleveland Clinic Lerner Research Institute
Friday, Nov 22
4:40 pm

IMMU-23 - Targeting metastatic and CNS tumors via mannan-BAM, TLR ligands and anti-CD40 antibody
Location: Grand Canyon 1-6
Herui Wang – NCI
Friday, Nov 22
4:45 pm

IMMU-09 - Combination Immune Treatment of a Highly Aggressive Orthotopic Murine Glioblastoma with Checkpoint Blockade and Multi-valent Neoantigen Vaccination
Location: Grand Canyon 1-6
Connor Liu – Washington University in St. Louis
Friday, Nov 22
4:50 pm

IMMU-45 - CAR-T treatment of novel mouse model of EGFRvIII⁺ GBM mirrors clinical trial outcomes and provides a syngeneic platform for the investigation of CAR-T mechanisms of action
Location: Grand Canyon 1-6
Polly Chuntova, PhD – University of California San Francisco
Friday, Nov 22
7:30 pm

IMMU-04 - Temporal and spatial modulation of the immune response of the murine Gl261 glioma tumour microenvironment
Location: Ballroom Lawn
Viive M. Howell – The University of Sydney (Kolling Institute of Medical Research)
Friday, Nov 22
7:30 pm

IMMU-06 - TTFields induces immunogenic cell death and STING pathway activation through cytoplasmic double-stranded DNA in glioblastoma cells
Location: Ballroom Lawn
Dongjiang Chen – Lilian Wells Department of Neurological Surgery, the University of Florida
Friday, Nov 22
7:30 pm

IMMU-08 - The antigenic landscape of glioblastoma - refining the targets for immunotherapy
Location: Ballroom Lawn
Konstantina Kapolou – University Hospital and University of Zurich, Department of Neurology, Laboratory of Molecular Neuro -Oncology
Friday, Nov 22
7:30 pm

IMMU-10 - Establishing Effective Models for Immunotherapy in GBM
Location: Ballroom Lawn
Daniel Zamler – The University of Texas MD Anderson Cancer
Friday, Nov 22
7:30 pm

IMMU-22 - Targeting non-canonical function of IDO1 in glioblastoma immunotherapy
Location: Ballroom Lawn
Lijie Zhai, PhD – Northwestern University, Feinberg School of Medicine, Department of Neurological Surgery
Friday, Nov 22
7:30 pm

IMMU-24 - A comprehensive in silico approach to discovering tumor rejection antigens in malignant brain tumors
Location: Ballroom Lawn
Changlin Yang – Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL 32610
Friday, Nov 22
7:30 pm

IMMU-26 - Radiation and temozolomide up-regulates CD70 expression and enhances CAR T- cell recognition in GBM
Location: Ballroom Lawn
Meng Na – University of Florida
Friday, Nov 22
7:30 pm

IMMU-32 - RNA-nanoparticle vaccines mediate T cell trafficking necessary for BBB passage and anti-glioma immune response
Location: Ballroom Lawn
Elias J. Sayour – University of Florida
Friday, Nov 22
7:30 pm

IMMU-36 - The role of PD-L1 in glioblastoma-derived extracellular vesicles in the induction of immunosuppressive monocytes.
Location: Ballroom Lawn
Benjamin T. Himes – Mayo Clinic
Friday, Nov 22
7:30 pm

IMMU-38 - CRISPR based genome editing of human T cells to target H3.3K27M mutation in gliomas
Location: Ballroom Lawn
Bindu Hegde – UCSF
Friday, Nov 22
7:30 pm

IMMU-42 - CD8+ T-cells mediate immunoediting, and influence genotype, tumor oncogenic pathways and microenvironment during progression of murine gliomas
Location: Ballroom Lawn
Victor A. Arrieta – Northwestern University
Friday, Nov 22
7:30 pm

IMMU-44 - Inhibiting immunosuppressive IDO1 in adults with malignant glioma – a moving target that changes with treatment, cell of origin, and aging.
Location: Ballroom Lawn
Derek Wainwright – Northwestern University, Feinberg School of Medicine, Department of Neurological Surgery
Friday, Nov 22
7:30 pm

IMMU-46 - Examination of the effects of Dexamethasone on the efficacy of immunotherapy in glioma using Gene-Mediated Cytotoxic Immunotherapy
Location: Ballroom Lawn
Marilin S. Koch – Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School
Friday, Nov 22
7:30 pm

IMMU-48 - Rational development and characterization of multivalent targeting tandem and parallel CAR T cells for glioma.
Location: Ballroom Lawn
Zev Binder – University of Pennsylvania
Saturday, Nov 23
11:40 am

IMMU-40 - Cancer immunoediting shapes the immune escape signature and clonal architecture in gliomas
Location: Grand Canyon Ballroom
Katrin Lamszus – Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
Saturday, Nov 23
5:40 pm

IMMU-05 - Disruption of the CCR2 chemokine receptor pathway overcomes therapeutic resistance to PD-1 blockade in malignant glioma
Location: Wildflower A
Joseph A. Flores-Toro, PhD – Department of Pharmacology & Therapeutics, Preston A. Wells Jr. Center for Brain Tumor Therapy, University of Florida
Saturday, Nov 23
5:44 pm

IMMU-12 - IL13Ra2-CAR T Cells Stimulate Endogenous Immune Responses against Murine Glioblastomas
Location: Wildflower A
Darya Alizadeh – City of Hope
Saturday, Nov 23
5:48 pm

IMMU-14 - Oncolytic virus expressing a positive immune checkpoint modulator as a therapeutic approach for DIPG
Location: Wildflower A
Virginia Laspidea – University Clinic of Navarra
Saturday, Nov 23
5:52 pm

IMMU-34 - ATRX mutations predict response to innate based therapy in glioma.
Location: Wildflower A
Seethalakshmi Hariharan – Duke University Medical Center
Saturday, Nov 23
5:56 pm

IMMU-39 - RNA loaded lipid-nanoparticles function as customizable immunotherapeutic vehicles against malignant gliomas
Location: Wildflower A
Elias J. Sayour – University of Florida
Saturday, Nov 23
5:00 pm

IMMU-03 - Suppression of Oncometabolite 2-Hydroxyglutrate Produced by Mutant IDH1 Glioma with AGI-5198 Enhances the Efficacy of Radiotherapy and Immune Checkpoint Blockade Eliciting Immunological Memory
Location: Ballroom Lawn
Padma Kadiyala – Department of Neurosurgery, University of Michigan Medical School,
Saturday, Nov 23
5:00 pm

IMMU-15 - A unique self-stimulative property of CD70 CAR advances T cell function and anti-tumor response in glioblastoma
Location: Ballroom Lawn
Linchun Jin – University of Florida
Saturday, Nov 23
5:00 pm

IMMU-17 - Targeting glioblastoma with DNAM-1-based chimeric antigen receptor (CAR) T cells
Location: Ballroom Lawn
Patrick Roth – Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich
Saturday, Nov 23
5:00 pm

IMMU-25 - Magnetic particle imaging for non-invasive tracking of adoptive cell transfer in cancer immunotherapy
Location: Ballroom Lawn
Angelie Rivera-Rodriguez – University of Florida
Saturday, Nov 23
5:00 pm

IMMU-27 - Immune Checkpoint Blockade of Ex Vivo Expanded T cells for Use in Adoptive Cellular Therapy (ACT) for Glioblastoma
Location: Ballroom Lawn
Elizabeth Ogando-Rivas – Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL 32610
Saturday, Nov 23
5:00 pm

IMMU-35 - Complement system and glioblastoma: an intricate relationship
Location: Ballroom Lawn
Sandeep Mittal – UT MD Anderson Cancer Center, Houston, Texas
Saturday, Nov 23
5:00 pm

IMMU-37 - Single-cell systems neuroimmunology reveals immunosuppressive correlates with ventricular stem cell niche contact in human glioblastoma
Location: Ballroom Lawn
Todd Bartkowiak – Vanderbilt University
Saturday, Nov 23
5:00 pm

IMMU-41 - RNA-modified T cells as professional antigen presenting cells.
Location: Ballroom Lawn
Fernanda Pohl-Guimarães – University of Florida
Saturday, Nov 23
5:00 pm

IMMU-43 - Polyamine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
Location: Ballroom Lawn
Jason Miska – Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University
Saturday, Nov 23
5:00 pm

IMMU-51 - Profiling the immune system in primary and recurrent glioblastoma
Location: Ballroom Lawn
Paul Tooney – The University of Newcastle
Sunday, Nov 24
9:55 am

IMMU-18 - Immunogenomic Responder Phenotype from a Phase I Trial of Anti-LAG3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM
Location: Grand Canyon 1-6
Christina Jackson, MD – Johns Hopkins University School of Medicine Department of Neurosurgery
Sunday, Nov 24
10:30 am

IMMU-01 - Myeloid-derived suppressor cell heterogeneity drives glioblastoma progression in a sex-dependent manner
Location: Grand Canyon 7
Defne Bayik – Cleveland Clinic Lerner Research Institute
Sunday, Nov 24
10:40 am

IMMU-02 - Neoantigens arising from alternative splicing events may be targeted by tumor infiltrating lymphocytes in glioblastomas
Location: Grand Canyon 7
Alexander H. Lee – University of California, Los Angeles
Sunday, Nov 24
10:50 am

IMMU-11 - Spatiotemporal immunogenomic analysis of the T-cell repertoire in IDH-mutant lower grade gliomas
Location: Grand Canyon 7
Michael Y. Zhang, MD, PhD – Department of Radiation Oncology, University of California, San Francisco
Sunday, Nov 24
11:00 am

IMMU-13 - Mechanisms of immunological escape during adoptive cellular therapy in high grade glioma
Location: Grand Canyon 7
Tyler Wildes, PhD – University of Florida
Sunday, Nov 24
11:10 am

IMMU-20 - Advanced Aging Increases Immunosuppressive IDO1 Levels That Are Uninhibited by IDO1 Enzyme Inhibitor Treatment in Models of Glioblastoma
Location: Grand Canyon 7
Erik Ladomersky, PhD – Northwestern University, Feinberg School of Medicine, Department of Neurological Surgery
Sunday, Nov 24
11:20 am

IMMU-31 - Driver gene mutations dictate the composition of the immune landscape of Glioblastoma and confer selective response to immunotherapy.
Location: Grand Canyon 7
Al Charest – Beth Israel Deaconess Medical Center
Sunday, Nov 24
11:40 am

IMMU-19 - Quinolinate-induced immune suppression in glioblastoma
Location: Grand Canyon 7
Pravin Kesawani – Beaumont Health
Sunday, Nov 24
11:45 am

IMMU-21 - Sequential two-receptor priming CAR system to overcome heterogeneous antigen expression
Location: Grand Canyon 7
Payal Watchmaker, PhD – University of California San Francisco
Sunday, Nov 24
11:50 am

IMMU-30 - Utilizing a novel mass cytometry-based immunomonitoring platform for the characterization of vaccine-reactive, epitope-specific CD8⁺T-cells in HLA-A*0201⁺ patients with K27M⁺diffuse midline gliomas
Location: Grand Canyon 7
Jared Taitt – UCSF
Sunday, Nov 24
11:55 am

IMMU-33 - Immune profiling reveals inhibitory macrophages and a distinct spatial distribution of immune cells in different types of brain metastases
Location: Grand Canyon 7
Jenny C. Kienzler – Department of Neurosurgery, University of California, Los Angeles
Sunday, Nov 24
12:00 pm

IMMU-49 - The selective enrichment of T cells targeting unknown brain cancer antigens via trogocytosis
Location: Grand Canyon 7
Ginger Moore – University of Florida
Sunday, Nov 24
12:05 pm

IMMU-50 - Systemic adoptive transfer immunotherapy with TCR-transduced T-Cells targeting NY-ESO-1 for meningioma
Location: Grand Canyon 7
Matthew Z. Sun, MD – University of California, Los Angeles
Innovations in Patient Care
Friday, Nov 22
2:20 pm

INNV-21 - In newly-diagnosed glioblastoma, frailty/sarcopenia predicts 30d morbidity & 30d, 90d, and overall mortality as accurately as current standards
Location: Grand Canyon 8-13
Hesham M. Zakaria – Henry Ford Hospital
Friday, Nov 22
7:30 pm

INNV-02 - Are we Aggressive with our Glioblastoma Patients: A Proposed Tool to Evaluate Centers Attitudes in Treatment of Glioblastoma
Location: Ballroom Lawn
Abdulrazag Ajlan, MD – King Saud University
Friday, Nov 22
7:30 pm

INNV-04 - IDH mutation prediction in glioma: A multimodal approach
Location: Ballroom Lawn
Dietmar Krex – Carl Gustav Carus Universitätsklinikum Dresden
Friday, Nov 22
7:30 pm

INNV-06 - Treatment response to bevacizumab over two years in a patient with genetically proven somatic neurofibromatosis type 2 mosaicism
Location: Ballroom Lawn
Ruthild G. Weber – Department of Human Genetics, Hannover Medical School
Friday, Nov 22
7:30 pm

INNV-08 - Validation of Readiband™ actigraph and associated sleep/wake classification algorithms in predicting cancer-related fatigue in high grade glioblastoma
Location: Ballroom Lawn
Megan E. Tipps – Allina Health
Friday, Nov 22
7:30 pm

INNV-10 - Safety of apixaban for venous thromboembolism prevention in patients with newly diagnosed glioblastoma
Location: Ballroom Lawn
Alissa A. Thomas – University of Vermont College of Medicine
Friday, Nov 22
7:30 pm

INNV-12 - Outcomes in a real-world practice for patients with primary glioblastoma: impact of a specialized neuro-oncology cancer care program
Location: Ballroom Lawn
Nilanjana Banerji – Allina Health
Friday, Nov 22
7:30 pm

INNV-14 - Adjuvant chemotherapy after severe myelotoxicity during temozolomide chemoradiation in gliomas. It is feasibile?
Location: Ballroom Lawn
Andrea Pace – Regina Elena National Cancer Institute.
Friday, Nov 22
7:30 pm

INNV-16 - Complete response of thalamic IDH wildtype glioblastoma after proton therapy followed by chemotherapy together with Tumor TreatingFields
Location: Ballroom Lawn
Marco Stein – Justus Liebig University
Friday, Nov 22
7:30 pm

INNV-18 - The Availability and Role of Clinical Pharmacists in the Ambulatory Neuro-Oncology Setting: An International Survey
Location: Ballroom Lawn
Mallika P. Patel – Duke University Medical Center
Friday, Nov 22
7:30 pm

INNV-20 - A systematic review of tumor treating fields therapy for primary and recurrent glioblastoma
Location: Ballroom Lawn
Pavan P. Shah – Johns Hopkins University School of Medicine
Friday, Nov 22
7:30 pm

INNV-22 - To treat or not to treat – treatment outcomes of very elderly glioblastoma patients
Location: Ballroom Lawn
Christian Senft – University Hospital Frankfurt
Friday, Nov 22
7:30 pm

INNV-26 - In vitro Chemo Resistance Profiles of Circulating Glial Cells Replicate Chemo Characteristics of Tumor Tissue
Location: Ballroom Lawn
Dadasaheb Akolkar – Datar Cancer Genetics Limited
Friday, Nov 22
7:30 pm

INNV-28 - Molecular testing in neuro-oncology – assessment of utility and practice patterns. A Society for Neuro-Oncology membership survey.
Location: Ballroom Lawn
Maciej M. Mrugala – Mayo Clinic
Friday, Nov 22
7:30 pm

INNV-30 - Response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutated glioblastoma: a case report
Location: Ballroom Lawn
Marina Kushnirsky – University of Miami/ Jackson Health System
Friday, Nov 22
7:30 pm

INNV-32 - Super-induction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ
Location: Ballroom Lawn
Mi-Yeon Jung, PhD – Mayo Clinic
Friday, Nov 22
7:30 pm

INNV-34 - Patterns of failure and development of a novel prognostic scoring system in elderly patients with glioblastoma – follow up on 10 year analysis of the BC Cancer Agency population.
Location: Ballroom Lawn
Andra V. Krauze – BC Cancer
Friday, Nov 22
7:30 pm

INNV-38 - Rate of EEG in glioma patients: should this be part of standard of care for new brain tumor patients?
Location: Ballroom Lawn
Wendy Sherman – Spectrum Health
Friday, Nov 22
7:30 pm

INNV-40 - Targeted Next Generation Sequencing of Pediatric High-Grade Glioma and Its Therapeutic Implications, MD Anderson Experience
Location: Ballroom Lawn
David McCall – The University of Texas MD Anderson
Friday, Nov 22
7:30 pm

INNV-42 - Venous thromboembolism risk assessment in patients with glioma
Location: Ballroom Lawn
Dusten J. Unruh – Northwestern University
Saturday, Nov 23
5:00 pm

INNV-01 - Ketogenic Metabolic Therapy significantly improves radiographic and clinical response to salvage temazolamide in patients with recurrent high grade gliomas
Location: Ballroom Lawn
Kris A. Smith – Barrow Neurological Institute
Saturday, Nov 23
5:00 pm

INNV-03 - A Microfluidic Culture Paradigm for the Ex Vivo Maintenance of Human Glioblastoma Tissue - A New GBM Model?
Location: Ballroom Lawn
Farouk Olubajo, MBBS, MD, FRCS – The Walton Centre NHS Foundation Trust
Saturday, Nov 23
5:00 pm

INNV-05 - Social media and “tweet chat analyses” to inform QOL and palliative care needs in patients with primary brain tumors
Location: Ballroom Lawn
Liz Salmi – OpenNotes / Beth Israel Deaconess Medical Center
Saturday, Nov 23
5:00 pm

INNV-07 - The Korean Society for Neuro-Oncology (KSNO) Guideline for Gliomas: version 2019.01
Location: Ballroom Lawn
YOUNG ZOON KIM – SUNGKYUKWAN UNIVERSITY
Saturday, Nov 23
5:00 pm

INNV-09 - Clinical efficacy of tumor treating fields for newly diagnosed glioblastoma
Location: Ballroom Lawn
Yang Liu – University of Rochester
Saturday, Nov 23
5:00 pm

INNV-11 - The risk of hemorrhage associated with thrombocytopenia in patients undergoing ommaya reservoir placement for intrathecal chemotherapy: a single institution retrospective analysis
Location: Ballroom Lawn
Arpan Patel – Cleveland Clinic Foundation
Saturday, Nov 23
5:00 pm

INNV-15 - Clinical data that matters: A distillation of neuro-oncology clinical trial inclusion criteria using machine learning
Location: Ballroom Lawn
James Snyder, DO – Henry Ford Health System
Saturday, Nov 23
5:00 pm

INNV-17 - Innovative educational approaches to enhance patient and caregiver understanding of Optune® for glioblastoma
Location: Ballroom Lawn
Melissa Shackelford – Novocure
Saturday, Nov 23
5:00 pm

INNV-19 - Surveying Bias in Neuro-Oncology and Society of Neuro Oncology (SNO) members: Gender and Beyond
Location: Ballroom Lawn
Priya Kumthekar – Northwestern University
Saturday, Nov 23
5:00 pm

INNV-23 - Glioblastoma and Facebook: An Analysis of Perceived Etiologies and Treatments.
Location: Ballroom Lawn
Naveen Kumar M. Reddy, B.S. M.S. – Frank H. Netter MD School of Medicine
Saturday, Nov 23
5:00 pm

INNV-27 - The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases.
Location: Ballroom Lawn
Nancy Wang – Massachusetts General Hospital
Saturday, Nov 23
5:00 pm

INNV-29 - Photodynamic therapy for malignant brain tumors
Location: Ballroom Lawn
Kazuhiro Tanaka – Department of Neurosurgery, Kobe University Graduate School of Medicine
Saturday, Nov 23
5:00 pm

INNV-31 - Accelerating neuro-oncology research and improving patient care through a robust data foundation
Location: Ballroom Lawn
Kristin Diefes Alfaro – UT MD Anderson Cancer Center, Houston, Texas
Saturday, Nov 23
5:00 pm

INNV-33 - Barriers to Accrual and Enrollment in Brain Tumor Trials
Location: Ballroom Lawn
Eudocia Q. Lee – Dana-Farber Cancer Institute
Saturday, Nov 23
5:00 pm

INNV-35 - Introducing the Educational Neuro-Oncology App
Location: Ballroom Lawn
Iyad Alnahhas – The Ohio State University
Saturday, Nov 23
5:00 pm

INNV-39 - The impact of multidisciplinary management on the overall survival of Glioblastoma and Anaplastic glioma patients in the era of Precision medicine-A Community physician's experience and Dilemma
Location: Ballroom Lawn
Tulika Ranjan – AHN Cancer Institute
Saturday, Nov 23
5:00 pm

INNV-41 - Prospective selection of recurrent glioblastoma patients for tailored therapies. Results of an institutional experience.
Location: Ballroom Lawn
Quintino Giorgio D'Alessandris – Department of Neurosurgery, Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore
Saturday, Nov 23
5:00 pm

INNV-43 - Improving Post Operative Follow-Up And Time To Adjuvant Treatment For High Grade Glioma
Location: Ballroom Lawn
Simon Khagi – University of North Caroline at Chapel Hill
Meningioma
Friday, Nov 22
7:30 pm

MNGI-02 - Features of tumor texture influence surgery and outcome in intracranial meningioma
Location: Ballroom Lawn
Franz Ricklefs – Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
Friday, Nov 22
7:30 pm

MNGI-04 - Patterns of failure and factors influencing local recurrence of meningioma treated with postoperative radiation therapy.
Location: Ballroom Lawn
Matthew Susko, MD, MS – University of California - San Francisco, Department of Radiation Oncology
Friday, Nov 22
7:30 pm

MNGI-05 - Combined multimodal treatment regimen in recurrent meningiomas
Location: Ballroom Lawn
Jose Carrillo – John Wayne Cancer Institute
Friday, Nov 22
7:30 pm

MNGI-06 - Efficacy of ¹⁷⁷Lu-Dotatate therapy in recurrent anaplastic meningioma
Location: Ballroom Lawn
Anza Zahid – Mayo Clinic
Friday, Nov 22
7:30 pm

MNGI-07 - Trimethylated H3K27 and EZH2 expression in meningioma: correlation with tendency to recur.
Location: Ballroom Lawn
Bianca Pollo – Fondazione IRCCS Istituto Neurologico C. Besta
Friday, Nov 22
7:30 pm

MNGI-08 - Pharmacokinetic analysis of ⁶⁸Ga-DOTATOC in meningiomas using PET/CT for assessment of somatostatin receptors and correlation with angiogenesis, inflammation and proliferation
Location: Ballroom Lawn
Asma Amy Bashir – Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Friday, Nov 22
7:30 pm

MNGI-10 - Atypical Meningioma: Early Outcomes With or Without Postoperative Radiation
Location: Ballroom Lawn
Peter C. Pan – New York Presbyterian Hospital-Columbia University Irving Medical Center
Friday, Nov 22
7:30 pm

MNGI-11 - High-grade and low-grade meningiomas harbor differing metabolomic profiles
Location: Ballroom Lawn
Garrett M. Fitzpatrick – University of Florida College of Medicine
Friday, Nov 22
7:30 pm

MNGI-14 - Prognostic Features of Malignant Meningioma: Evaluation of aggressive meningiomas within a large rural hospital system database and first report of a metastatic chordoid meningioma to the lung
Location: Ballroom Lawn
Na Tosha N. Gatson – Geisinger Neuroscience & Cancer Institutes
Saturday, Nov 23
1:40 pm

MNGI-09 - Meningioma with Multiple Drivers: Genomic Landscape and Clinical Correlations
Location: Grand Canyon 1-6
Chang Li – Department of Neurosurgery, Yale School of Medicine
Saturday, Nov 23
1:50 pm

MNGI-01 - A Phase 0 Trial of Ribociclib in Aggressive Meningioma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
Location: Grand Canyon 1-6
Nader Sanai, MD – Ivy Brain Tumor Center, Barrow Neurological Institute
Saturday, Nov 23
1:55 pm

MNGI-13 - Dynamic imaging of meningioma with 3’-deoxy-3’-[¹⁸F]-fluorothymidine using positron emission tomography: a possible predictor of tumor growth
Location: Grand Canyon 1-6
Asma Amy Bashir – Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Saturday, Nov 23
2:00 pm

MNGI-03 - Estrogen hormone replacement therapy in incidental meningioma - a growth rate analysis
Location: Grand Canyon 1-6
David O. Kamson, MD PhD – Department of Neuro-Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Saturday, Nov 23
2:10 pm

MNGI-12 - Pleiotropic MLLT10 variation confers risk of meningioma, breast, and ovarian cancers
Location: Grand Canyon 1-6
Kyle M. Walsh – Duke University School of Medicine
Molecular Pathology and Classification - Adult and Pediatric
Friday, Nov 22
3:15 pm

PATH-15 - Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
Location: Grand Canyon 7
Ho-Keung Ng, MD, PhD – THE CHINESE UNIVERSITY OF HONG KONG
Friday, Nov 22
3:25 pm

PATH-42 - IDH-mutant lower-grade astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations
Location: Grand Canyon 7
Kay Ka-Wai Li – THE CHINESE UNIVERSITY OF HONG KONG
Friday, Nov 22
3:45 pm

PATH-32 - Genomic landscape and biology of medulloblastoma in adults
Location: Grand Canyon 7
Torsten Pietsch – University of Bonn Medical School, Department of Neuropathology
Friday, Nov 22
3:55 pm

PATH-54 - Multi-dimensional molecular characterization of patient-matched medulloblastoma at diagnosis and relapse
Location: Grand Canyon 7
Rahul Kumar – St. Jude Children's Research Hospital
Friday, Nov 22
4:05 pm

PATH-18 - CSF-derived circulating tumor DNA reflects disease course and clonal evolution in medulloblastoma
Location: Grand Canyon 7
Anthony P.Y. Liu, MBBS, MMedSc – St. Jude Children's Research Hospital
Friday, Nov 22
4:35 pm

PATH-63 - Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized treatment sensitivity and survival
Location: Grand Canyon 7
Leslie L. Muldoon, PhD – Oregon Health & Science University
Friday, Nov 22
4:40 pm

PATH-39 - DNA mismatch repair enzyme immunohistochemistry is a rapid, effective screening test for hypermutated gliomas
Location: Grand Canyon 7
Matthew McCord – Northwestern University
Friday, Nov 22
4:45 pm

PATH-48 - The DNA methylation landscape of core and peripheral diffuse glioma regions shows little spatial subtype heterogeneity after considering tumor purity
Location: Grand Canyon 7
Niels Verburg – Amsterdam UMC
Friday, Nov 22
4:50 pm

PATH-44 - Multiple biomarker algorithm based on CXCL13, IL-10, IL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose central nervous system lymphoma
Location: Grand Canyon 7
Takashi Sasayama – Department of Neurosurgery, Kobe University Graduate School of Medicine
Friday, Nov 22
7:30 pm

PATH-12 - Identifying Molecular Prognostic Markers in IDHwt Glioblastoma
Location: Wildflower C
Iyad Alnahhas – The Ohio State University
Friday, Nov 22
7:54 pm

PATH-05 - Rapid Simultaneous IDH Mutation and MGMT Methylation Status Assessment in Glioma Patients using CRISPR-Cas9-targeted Nanopore Sequencing
Location: Wildflower C
Analiz Rodriguez, MD, PhD – University of Arkansas for Medical Sciences
Friday, Nov 22
7:58 pm

PATH-13 - Sex-linked tumoral MGMT status and outcomes in newly diagnosed glioblastoma
Location: Wildflower C
Addison E. Barnett – Cleveland Clinic
Friday, Nov 22
8:02 pm

PATH-53 - Immunological profiling of mutational and transcriptional subgroups in pediatric and adult high-grade gliomas
Location: Wildflower C
Malte Mohme – University Medical Center Hamburg Eppendorf
Friday, Nov 22
8:06 pm

PATH-55 - Mutations of H3.3 and H3.1 in a large cohort of gliomas
Location: Wildflower C
Ashley L. Sumrall – Levine Cancer Institute
Friday, Nov 22
7:30 pm

PATH-02 - A combination of MGMT methylation and NFKBIA copy number alteration refines prognostication of IDH-wt glioblastomas
Location: Ballroom Lawn
Toru Umehara – Departments of Neurosurgery, Osaka University Graduate School of Medicine
Friday, Nov 22
7:30 pm

PATH-04 - Influence of individual CpG methylation status of the MGMT promotor on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment
Location: Ballroom Lawn
Sebastian Siller – University Hospital, Ludwig-Maximilian-University Munich
Friday, Nov 22
7:30 pm

PATH-06 - A targeted NGS-based overall solution to support diagnostics and therapy prediction in neurooncology: Considerations for a flexible and cost-efficient platform choice and panel design.
Location: Ballroom Lawn
Markus J. Riemenschneider – Regensburg University Hospital, Department of Neuropathology
Friday, Nov 22
7:30 pm

PATH-08 - Challenges in optimization of MGMT promoter methylation assays for development of companion diagnosis in glioblastoma
Location: Ballroom Lawn
Motoo Nagane – Department of Neurosurgery, Kyorin University Faculty of Medicine
Friday, Nov 22
7:30 pm

PATH-10 - Relationship between cytogenetic complexity and peritumoral edema in high-grade astrocytoma
Location: Ballroom Lawn
Kyoung Su Sung, MD – Department of neurosurgery, Dong-A University Hospital
Friday, Nov 22
7:30 pm

PATH-14 - Immunohistochemical analysis of tumor associated macrophage induced after carmustine wafer implantation in human glioblastoma
Location: Ballroom Lawn
Ichiyo Shibahara – Department of Neurosurgery, Kitasato University School of Medicine
Friday, Nov 22
7:30 pm

PATH-16 - Histopathological ependymoma variants are associated with distinct clinical parameters and DNA methylation patterns
Location: Ballroom Lawn
Julia E. Neumann – (1) Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Friday, Nov 22
7:30 pm

PATH-20 - Investigation of clinically aggressive spinal cord ependymoma through methylation analysis
Location: Ballroom Lawn
Nicole Briceno – Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Friday, Nov 22
7:30 pm

PATH-22 - Multiplexed immunohistochemistry and the immune microenvironment of primary central nervous system tumors
Location: Ballroom Lawn
Carli Bullis – Oregon Health and Science University
Friday, Nov 22
7:30 pm

PATH-24 - CXCR4 is a Potential Therapeutic Target for Glioblastoma and Diffuse Intrinsic Pontine Gliomas
Location: Ballroom Lawn
Takeshi Takayasu – University of Texas Health Science Center
Friday, Nov 22
7:30 pm

PATH-26 - Characterizing Genetic difference in Cystic Glioblastoma
Location: Ballroom Lawn
zhihua Chen – Youjiang Medical University for Nationalities
Friday, Nov 22
7:30 pm

PATH-28 - Angiotensinogen promoter methylation to predict bevacizumab response in recurrent glioblastoma patients
Location: Ballroom Lawn
Thomas Urup – Department of Radiation Biology and Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark
Friday, Nov 22
7:30 pm

PATH-30 - Targeted therapies for Pediatric Low-grade gliomas: A Case Series
Location: Ballroom Lawn
ANDREW WALTER – NEMOURS/AI DUPONT HOSPITAL FOR CHILDREN
Friday, Nov 22
7:30 pm

PATH-34 - Clinicopathologic, molecular and immunological characterization of diffuse midline gliomas: is there a prognostic significance?
Location: Ballroom Lawn
Niveditha Manjunath – All India Institute of Medical Sciences
Friday, Nov 22
7:30 pm

PATH-36 - Machine learning to detect gliomas in urine-based liquid biopsy
Location: Ballroom Lawn
Yotaro Kitano – Department of Neurosurgery, Nagoya University Graduate School of Medicine.
Friday, Nov 22
7:30 pm

PATH-38 - Rosette-forming glioneuronal tumor is defined by FGFR1 activating alterations with frequent accompanying PI3K and MAPK pathway mutations
Location: Ballroom Lawn
David Solomon – University of California - San Francisco
Friday, Nov 22
7:30 pm

PATH-40 - Profiling pleomorphic xanthroastrocytoma with DNA methylation and exploring the tumor immune cell-type composition with methylation-based deconvolution
Location: Ballroom Lawn
Karen Tang – New York University Langone Health
Friday, Nov 22
7:30 pm

PATH-50 - Routine molecular diagnosis of glioma patients using a glioma-specific NGS panel
Location: Ballroom Lawn
Koji Yoshimoto – Graduate School of Medical and Dental Sciences, Kagoshima University
Friday, Nov 22
7:30 pm

PATH-52 - ANAPLASTIC PILOMYXOID ASTROCYTOMA HARBORING BRAF FUSION, PTEN AND TERT MUTATIONS
Location: Ballroom Lawn
Trisha Kissoon-Larkin – University of Florida
Friday, Nov 22
7:30 pm

PATH-56 - Pyrosequencing method for rapid detection of KIAA1549-BRAF fusion genes in pediatric brain tumors
Location: Ballroom Lawn
Yuzaburo Shimizu – Juntendo University Faculty of Medicine
Friday, Nov 22
7:30 pm

PATH-58 - Reappraisal of histological features and molecular analysis of lower grade gliomas and association with overall survivals
Location: Ballroom Lawn
Eriel S. Pareira, MD – Keio University School of Medicine, Tokyo
Friday, Nov 22
7:30 pm

PATH-60 - Primary CNS lymphoma preceded by acute demyelination
Location: Ballroom Lawn
Justin Low – Duke University
Friday, Nov 22
7:30 pm

PATH-62 - Quantitative analysis of sex-associated MGMT methylation in newly diagnosed glioblastoma
Location: Ballroom Lawn
Addison E. Barnett – Cleveland Clinic
Friday, Nov 22
7:30 pm

PATH-64 - Prospective, Blinded Plasma Based Analysis for Diagnosis of Newly Diagnosed Glioma
Location: Ballroom Lawn
Ian Lee, MD – Henry Ford Hospital
Saturday, Nov 23
5:00 pm

PATH-01 - MGMT methylation cutoff value in quantitative analysis related to prognosis of newly diagnosed glioblastoma
Location: Ballroom Lawn
Jun-ichi Adachi – Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center
Saturday, Nov 23
5:00 pm

PATH-03 - Differences in clinical course of group-A and group-B posterior fossa ependymoma (PFA, PFB) as defined by H3K27me3 immunohistochemical analysis
Location: Ballroom Lawn
Ushio Yonezawa – Hiroshima University
Saturday, Nov 23
5:00 pm

PATH-07 - Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma
Location: Ballroom Lawn
P.J. Cimino – University of Washington, Department of Pathology
Saturday, Nov 23
5:00 pm

PATH-09 - MGMT promoter methylation is a strong prognostic factor for survival after progression in high grade gliomas
Location: Ballroom Lawn
Yanwei Liu – Department of Radiation Therapy, Beijing Tiantan Hospital, Capital Medical University
Saturday, Nov 23
5:00 pm

PATH-11 - The prognostic role of IDH mutations in homogeneously treated patients with malignant diffuse astrocytomas.
Location: Ballroom Lawn
Christian Hartmann, MD – Division of Neuropathology, Department of Pathology, Hannover Medical School
Saturday, Nov 23
5:00 pm

PATH-17 - Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or cytotoxic therapies.
Location: Ballroom Lawn
Laura E. Donovan – Columbia University Irving Medical Center
Saturday, Nov 23
5:00 pm

PATH-19 - Tumor heterogeneity in gliomas: a pilot study of histopathology-associated proteome profiles assessed by liquid chromatography tandem mass spectrometry of FFPE samples.
Location: Ballroom Lawn
Aline P. Becker, MD PhD – OSUCCC
Saturday, Nov 23
5:00 pm

PATH-21 - Clinical utility of DNA methylation profiling for diagnosis of challenging central nervous system tumors: The Toronto experience
Location: Ballroom Lawn
Jeffrey A. Zuccato, MD – MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network
Saturday, Nov 23
5:00 pm

PATH-23 - Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH-wildtype astrocytomas
Location: Ballroom Lawn
Andrew L. Lin – Memorial Sloan Kettering Cancer Center